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ABSTRACT OF DISSERTATION

TARGETING THE CELLULAR REDOX ENVIRONMENT: A NOVEL APPROACH
FOR THE TREATMENT OF HEMATOPOIETIC NEOPLASMS
Hematopoietic stem cells (HSCs) that function to maintain the hematopoietic
compartment through self-renewal and differentiation capacities, as well as their
downstream progeny, are susceptible to transformation resulting in the generation of the
leukemic stem cell (LSC). Chief in the factors that control HSC regulation and protection
of the HSC compartment is the cellular redox environment. Deregulation of the
Hematopoietic Stem/Progenitor Cell (HSPC) redox environment results in loss of HSPC
function and exhaustion. The characteristic developments of HSPC exhaustion via
exposure to redox stress closely mirror phenotypic traits of hematopoietic malignancies,
presenting the HSPC/LSC redox environment as a potential therapeutic target. While
myelosuppression and HSPC exhaustion are detrimental side effects of classical
chemotherapies, new approaches that differentially modify the HSPC/LSC redox
environment may demonstrate LSC cytotoxicity while offering protection of normal HSPC
function via differential activation of internal signaling pathways. Precisely how the redox
environment and downstream signaling events are affected by these treatments remains
unclear; thus highlighting the need for robust methods that evaluate the HSPC/LSC redox
state. Because the glutathione (GSH), glutathione disulfide (GSSG) redox couple heavily
contributes to the management of HSPC function and redox environment, characterizing
the GSH/GSSG redox potential at the HSPC level would provide great insight for
therapeutic opportunities. However, accurate measurement the GSH/GSSG redox potential
within HSPCs/LSCs has been difficult due to their inherently low numbers. Here, we
describe the development and validation of a sensitive method used for the direct and
simultaneous quantitation of both oxidized and reduced GSH via LC-MS/MS. We use these
methodologies to establish a difference in GSH-GSSG half-cell reduction potentials
between normal and malignant HSPCs and examine the therapeutic effect of a redox active
MnSOD mimetic, Mn(III) mesotetrakis (N-n-butoxyethylpyridinium-2yl) porphyrin,
MnTnBuOE-2-PyP5+ (MnP), within these populations in vitro as well as within a human
xenograft model in vivo. MnP demonstrates significant cytotoxic effects in several

malignant models, while inducing an opposite cytoprotective effect in normal HSPC
populations. The GSH/GSSG redox balance, specifically managed by glutathione
reductase activity, is identified as a determining factor of MnP efficacy in various
malignant populations. Treatment of the human myelodysplastic cell line (MDSL) offers
mechanistic insights into MnP efficacy through hydrogen peroxide mediated activation of
activator protein 1 (AP-1) signaling. We identify the redox dependent activation of JunB,
a known regulator of normal myeloid lineage HSC proliferation, as a transcriptional
mechanistic mediator of MnP treatment induced AP-1 signaling resulting in malignant
cytotoxicity. The development of this novel method allowing for the identification of
targetable differences between normal and malignant cell populations has provided insight
to the underpinnings of potential redox based therapies. Additionally, the finding that MnP
can target varying cellular redox states and exert selective cytotoxicity in malignant over
normal populations by re-gaining lost control of AP-1 signaling demonstrates the potential
for development of safe therapeutics within a variety of clinical applications.

Key Terms: Hematopoietic Stem Cell, Cellular Redox State, Glutathione, JunB, MDS,
Chemoresistance
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Chapter One: Redox Active Compounds in Normal and Malignant Hematopoietic
Stem Cells.
Introduction
The hematopoietic compartment contains a tightly regulated hierarchy of cell types
responsible for the function and maintenance of the bone marrow and blood systems. All
peripheral blood cells, both the myeloid and lymphoid lineage, differentiate from a
common pool of hematopoietic stem and progenitor cells (HSPCs) which reside within
the bone marrow (74, 198). This pool of HSPCs can be broken down into three subsets of
cell types: the long-term hematopoietic stem cell (LT-HSC), short term hematopoietic
stem cell (ST-HSPC), and the multipotent progenitor cell (MPP). Two distinct progenitor
cell populations emerge from the MPP pool: the common lymphoid progenitors (CLPs)
and common myeloid progenitors (CMPs). Differentiation from these progenitor cell
populations eventually results in the establishment of peripheral effector cell populations
within each lineage, such as B and T cells within the lymphoid lineage or erythrocytes
and neutrophils within the myeloid lineage (1, 74, 199). There are several phenotypic and
functional facets that define the HSPC populations individually and as a whole. The
central defining characteristics of hematopoietic stem cells, particularly those within the
long-term population, are the ability to self-renew while, at the same time, limit the size
of the HSPC population and demonstrate the potential to differentiate into any mature
cell type within the hematopoietic system (Figure 1.1) (1, 16, 74, 131, 198, 199).
Short-term hematopoietic stem and progenitor (ST-HSPC) populations have the capacity
to maintain normal hematopoiesis for a period of 6 to 8 weeks. Serial transplant studies in
vivo have identified the long-term hematopoietic stem cell (LT-HSC) as the population
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and cell type which can sustain normal hematopoiesis throughout an organism’s entire
lifespan. This fact demonstrates a loss of HSC self-renewal capacity as a function of
increased cellular differentiation. For these reasons, normal LT-HSC function must be
maintained throughout the lifespan of an organism. This elucidates the LT-HSCs as the
only population that holds true characteristics of the hematopoietic stem cell (HSC).
Because self-renewal and differentiation of long-term and short-term hematopoietic stem
and multipotent progenitor cell populations is essential to normal hematopoietic function,
we define this entire population as the hematopoietic stem/progenitor cells (HSPCs) and
reserve the term HSC for the true LT-HSC populations.
Loss of normal LT-HSC and ST-HSPC function is a hallmark of natural stem cell aging
and several hematopoietic disorders, most notably the development and progression of
hematopoietic malignancies (1, 6, 16, 74, 86, 120, 131, 198, 199, 223, 233, 248). Within
these cancers, normal hematopoietic regulation is lost, yet disease still progresses through
the differentiation and clonal expansion of progenitor cell pools eventually leading to a
lack of terminal differentiation to functional cell types within the periphery. This
observation led to the identification of the cancer stem cell (CSC) or more specifically, the
leukemic stem cell (LSC) (4, 86, 87, 167, 186, 190, 204, 223, 248). Although we know that
hematopoietic neoplasms are driven by LSC populations, developing therapies that treat
LSC pools as entities separate from normal HSPCs has been difficult. Thus, little progress
has been made in the development of therapies that both eradicate malignant HSPCs while,
at the same time, protect or pose no detriment to healthy HSPC populations within a single
patient.

2

There is a heterogeneous and diverse set of cytogenetic abnormalities within various
hematopoietic cancers that, in some cases, may lend themselves to personalized treatment
plans. However, intrinsic characteristics that separate normal HSPCs from their
malignant counter parts are becoming more relevant (11, 17, 18, 24, 102, 146, 172, 216).
The identification of these differences will lead to the development of safe therapeutics
that have broad implications for treatment of several hematopoietic neoplasms across
patient populations. Chief in the differences between normal and malignant HSPCs is the
generation of reactive species and the management of the cellular redox environment (8,
33, 88, 100, 110, 147, 148, 167, 186, 189, 204, 216, 221, 226). It has been well
established that cancer cells demonstrate elevated levels of reactive species generation
and a difference in basal redox environment as compared to their normal counter parts.
This difference is heavily rooted in an increased metabolism and production of reactive
oxidative species such as superoxide and hydrogen peroxide, which in turn, leans on the
cellular antioxidant capacity and thus, enhances the need for reducing species such as
glutathione (GSH). The result is an unbalance in equilibria that stresses both sides of
cellular oxido-reduction capacity, herein we refer to this stress imbalance simply as redox
stress. In fact, the malignant hematopoietic phenotype mirrors the changes in normal
hematopoietic architecture brought on by increased production of redox stress, which
results in alterations to the HSPC redox environment (87, 90, 92, 165, 189, 221). This
fact has recently presented researchers with a druggable target in which a therapeutic
index can be defined that exploits the malignant cell redox environment while leaving
normal cell populations unharmed (88). This is accomplished by examining the effects of
redox active compounds in both normal and malignant hematopoietic stem and
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progenitor cell populations. Redox active compounds have traditionally been defined as
those which can undergo single electron transfers acting as either an oxidizing or
reducing agent. These compounds include nitroxides such as Tempol, flavonoids such as
oxorylin or baicalein, and those with transition metal centers, such as Mn (III) mesotetrakis(N-(n-butoxyethyl)pyridinium-2-yl) porphyrin (MnTnBuOE), capable of cycling
through multiple oxidation states acting as active sites for therapeutic efficacy (12-14, 67,
160, 210, 211, 229, 232, 252). Other compounds, such as doxorubicin, may transition
through structural changes as a result of electron exchange via metabolism (47, 50, 68,
114, 135, 136, 246). Additionally, we consider those compounds that affect the cellular
redox environment by actively modifying concentrations of cellular reductants or those
which inhibit normal antioxidant enzyme function, such as Buthionine Sulfoximine
(BSO) or Parthenolide (PTL), although actual oxido-reduction reactions do not directly
result from the chemistry of the molecules themselves (90, 163). In this review, we offer
a concise summary of key studies examining the effects of endogenous mechanisms and
redox active compounds resulting in changes to the cellular redox environment of normal
and malignant HSPCs. Furthermore, we present the HSPC cellular redox environment as
a druggable target that allows for effective intervention within malignant populations
while leaving normal HSPC populations unharmed.
Redox Regulation and Redox Active Compounds Affect in Normal HSC Function
The production and elimination of the initial and ensuing reactive species are the
cornerstones of cellular redox environment management. Here, metabolic byproducts
.
.
such as O2 - (superoxide) and H2O2 (hydrogen peroxide), as well as OH (hydroxyl
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radical), and ONOO- (peroxynitrite) are the main reactive species responsible for
oxidative damage, including DNA oxidation, lipid peroxidation, and protein oxidation as
well as nitration (221). As a result, an increase in metabolic activity and reactive species
generation is closely associated with an increase in cellular proliferation and
differentiation (92, 165, 198, 219). It should come as no surprise then that varying
concentrations of the original redox active compound, molecular oxygen (O2),
significantly affects cellular redox status and HSPC proliferation. The bone marrow
niche, or extracellular components surrounding HSPCs, and peripheral tissues have
oxygen tensions ranging from 1-7%. In vitro study of primary normal and malignant
HSPCs, as well as various culture lines, has demonstrated the beneficial effects of a
hypoxic environment (28, 37, 38, 80, 81, 191, 194). Both normal and malignant HSCs
benefit from growth conditions that have oxygen concentrations ranging from 1-3%,
compared to cultures at normoxic (5%) and atmospheric (21%) O2 concentrations (40,
92, 164, 205, 218). Interestingly, a low oxygen environment leads to a decrease of
glutathione levels, as well as antioxidant enzyme expression and function (29, 57, 149).
Primitive HSC populations have been thought to be refractory to induction of oxidative
stress, due to their quiescent state, antioxidant capacity, and local niche environment.
However, their environment may be a key factor in keeping HSCs sensitive to redox
stress. This facet of the bone marrow environment has potential in allowing for the
development of differential sensitivities to redox insult between normal and malignant
HSC as well as HSPC populations (Figure 1.2).
CD34+ HSPCs express higher levels of superoxide dismutase (SOD1 and SOD2) and
Catalase (CAT) relative to other antioxidant enzymes, such as, glutathione peroxidases
5

(GPx), glutathione-S-transferases (GSTs), glutathione reductase (GR), thioredoxin (TXN)
and thioredoxin reductase (TXNR) utilized for the removal of hydrogen peroxide as well
as other radicals and reactive species (Figure 1.3) (163). However, the expression level of
antioxidant defense enzymes such as SOD and CAT is lower in the primitive LT-HSC
compartment in comparison to their downstream differentiated progeny (6, 134, 221).
This means that if these defense enzymes fail, a significant buildup of primary and
secondary reactive species may occur, thus, quickly and, potentially irreversibly, altering
the redox environment within HSCs. Additionally, hematopoietic malignancies are
generally typified by the uncontrolled clonal expansion of HSPC populations. Therefore,
primitive malignant populations may, themselves, express low levels of antioxidant
enzymes, such as SOD or catalase. This would then result in higher levels of downstream
reducing agents such as the GSH/GSSH redox couple.
In the past decade, several key studies have identified management of the HSPC redox
environment as a crucial factor in the maintenance of the HSPC population. The HSPC
compartment itself contains cell populations that can be separated based on their ROS
levels and redox environments. Using 2’-7’-dichlorofluorescence diacetate (DCF-DA),
Jang and co-workers were able to separate two HSPC populations characterized by high
and low levels of ROS (92). These two populations display distinct differences in HSPC
function. Limiting dilution transplantation assays showed that HSPCs with low levels of
ROS repopulated recipient mice significantly better than HSCs with high levels of ROS.
This characteristic was also carried over to secondary and tertiary transplant recipients.
Additionally, the ROS low population contained more primitive long-term cultureinitiating cells (LTC-ICs) and resulted in better multilineage reconstitution (92).
6

Interestingly, upon transplantation the ROS high population resulted in lineage
reconstitution that favored elevated myeloid development. Conversely, ROS low cells
favored lymphoid lineage development. This indicates a potential for the development of
myeloid lineage malignancies upon redox deregulation within the normal HSPC
populations. The ROS high population demonstrated elevated levels of p38 activity,
elevated expression of p16 and lower levels of p53 expression. The LTC-IC capacity of
the ROS high population did respond to treatment with either a p38 MAPK inhibitor, the
GSH precursor N-acetyl-L-cysteine (NAC), or Rapamycin (92). This indicates that
buffering the HSPC redox environment can improve normal HSPC function. Thus, as one
might expect, NAC treatment aids the engraftment of normal human HSPCs isolated
from human cord blood into recipient mice. These results are demonstrated even in the
highly-enriched Lin- CD34+ CD38- CD90+ CD45RA+ CD49f+ Rholow HSC population
indicating exogenous protection against reactive species challenge and can independently
improve HSC function (85).
In 2007, Ito and colleagues utilized the Atm -/- mouse model to demonstrate that an
elevation of ROS activated p38 MAPK signaling, resulting in a loss of normal HSC
maintenance as well as quiescence eventually leading to HSPC senescence (90). They
found that depletion of cellular glutathione (GSH) via buthionine sulfoximine (BSO)
treatment lead to an increase in H2O2 within the HSPC Lin-/ Sca-1+/c-Kit+ (LSK)
population resulting in an increased expression of cell cycle regulators p15INK4B p16INK4A,
p18INK4C, and p19ARF. This lead to a loss of HSPC function; yet the upregulation of tumor
suppressor proteins was reversed by treatment with NAC or a p38 MAPK inhibitor.
These effects were not demonstrated in differentiated cell populations (90). Similarly,
7

ROS accumulation, p15INK4B, p16INK4A, p18INK4C, and p19ARF upregulation and loss of
HSPC function were demonstrated in Atm -/- mice. Within this model, treatment with a
p38 MAPK inhibitor both before and after transplant recovered HSC function in Atm -/mice, compared to wild type controls. Using NAC and p38 MAPK inhibitor treatments,
this study also demonstrated that ROS mediated p38 activation is responsible for a loss of
HSPC quiescence (90). Interestingly, hydrogen peroxide oxidation of ATM results in
internal disulfide crosslinking and dimer formation that leads directly to ATM activation
independent of DNA double strand breaks (78). Results found by Ito and colleagues are
very similar to those found by Myamoto and colleagues using a Foxo3a-/- mouse model.
These studies demonstrate FOXO3A regulation of HSC function. Importantly FOXO3A
operates downstream of PTEN/PI3K/AKT pathway, and loss of FOXO3A activity results
in HSC exhaustion and activation of the p38 MAPK pathway (137).
Just as these phenomena have been demonstrated in mice, human cells subject to serial
transplantation in mice demonstrate similar characteristics. Serial transplantation of
human Lin- CD34+ CD38- HSCs lose their ability to repopulate the bone marrow (245).
This loss of HSC function in human cells is accompanied by an accumulation of
oxidative DNA damage, characterized by an increase in γH2AX foci, as well as an
increase in the expression of cell cycle inhibitors p16INK4A, p14ARF, and p21CIP (245).
The formation of these DNA damage foci are recapitulated in normal human HSCs
treated with BSO. Upon formation, DNA damage repair enzymes, ATM, p53 binding
protein (53BP1), CHK2, and FOXO3A are recruited to these DNA damage foci.
Furthermore, examination of the highly-enriched Lin- CD34+ CD38- CD90+ CD45RA+
HSC population showed that although damage is seen in both the stem and progenitor
8

cell (CD34+ CD38+) populations, only the HSC compartment undergoes cell cycle arrest
and apoptosis. Additionally, HSC populations recover more slowly than progenitor
populations after the oxidative insult is removed. Consistent with other studies, addition
of NAC as a protecting agent preserves HSC function in correlation with decreased
accumulation of DNA damage foci, even in the face of oxidative insult (245). Control of
DNA damage response can also be managed via the polycomb repressor (BMI1)
signaling via control of INK4A/ARF (CHK2) proteins. A separate study indicates that
loss of BMI1 function results in mitochondrial dysfunction and accumulation of ROS,
and loss of HSPC self-renewal and differentiation, a phenotype that can be partially
restored by treatment with NAC or the deletion of the Chk2 gene itself (121).
Clearly the accumulation of oxidative damage incurs a detrimental effect on HSC
function, and as one may anticipate, NRF2 activity has been identified as a major
regulator of the HSC redox environment and HSC function (106, 132, 228). Tsai and
colleagues used the Nrf2-/- mouse to demonstrate familiar effects on HSC function. These
studies elegantly showed that the loss of NRF2 resulted in an increase in the Lin- sca-1+
c-kit+ (LSK) population, but only within the ST-HSC and MPP compartments, not within
the LT-HSC population (219). Furthermore, Nrf2-/- mice demonstrated an increase in both
the common myeloid, granulocyte-macrophage, megakaryocyte-erythroid (CMP, GMP,
MEP) and lymphoid (LMPP, CLP-1, CLP-2) progenitor cell populations. Although
progenitor pools underwent significant expansion, the primitive LT-HSC populations
were unchanged. However, Ki-67 analysis, 5-FU pulse experiments, and culture in OP9DL1 revealed that NRF2 regulates HSPC proliferation and differentiation resulting in
diminished quiescence and increased differentiation within the most primitive LT-HSC
9

populations (219). Importantly, NRF2 deficient HSPCs also significantly underperformed
in colony formation and in vivo transplant assays indicating that not only does NRF2
regulate proliferation and differentiation, but also regulates HSPC self-renewal and
function. Proliferation analysis via co-culture of deficient cells with WT counterparts
demonstrated a proliferative advantage for the Nrf2-/- cells (219). Chimeric studies
showed that the proliferative advantage is generated from within the HSPC itself and
does not result from signals received from the bone marrow environment. Moreover, the
loss of NRF2 results in a decreased bone marrow homing effect implying that NRF2 even
regulates the retention of HSPCs in bone marrow (219). This homing effect is linked to
the loss of CXCR4 expression resulting in deficient chemotaxis abilities in Nrf2-/- HSPCs
(60, 219).
The studies discussed above have laid the groundwork for a clear understanding of how
the HSPC redox environment affects normal HSPC regulation and function. Ultimately,
dysregulation of HSPC redox balance results in well-defined changes to HSPC
populations. As previously noted, the resulting alterations to HSPC populations mimic
those demonstrated in several disease states; most notably, the myeloproliferative
disorders. Clearly, regulating the cellular glutathione pool is required for faithful
management of ROS and HSPC function. HSPCs that undergo redox deregulation
resulting in an increase in ROS seem to demonstrate a natural response that functions
through the p38 MAPK signaling as well as FOXO and ATM DNA damage response
pathways (Figure 1.4) (90, 92, 137). This results in loss of HSPC quiescence and
function. Despite the perception that HSPCs maintain robust function as a result of their
protected location and their highly quiescent state, we now know that HSPCs not only
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rely on intrinsic signaling but that HSPCs are more sensitive to redox stress than
previously thought (245). These facets are highlighted by improving HSPC function
through buffering redox capacity but also by the result of losing major regulatory control
over redox environment management via transcription factors such as NRF2 (85, 219).
Thus, redox modulators, such as BSO, which induce strong conditions of oxidative stress,
work to the detriment of normal HSPC function. Conversely, compounds such as NAC
that provide antioxidant aid, improve HSPC function.
Chemotherapeutics and Normal HSCs
The work summarized above demonstrates the importance of HSPC redox regulation in
maintaining normal HSPC function. Normal HSPC toxicity and functional exhaustion is a
significant problem underlying the use of traditional chemotherapeutics for the treatment
of hematopoietic malignancies. Most chemotherapies currently utilized for the treatment
of the hematopoietic malignancies are not designed to manipulate the cellular redox
environment of the HSPC; rather, they target DNA synthesis or immune function.
However, we now know that many cancer therapeutics do in fact impact the redox milieu
of target and normal tissues. These redox active therapeutics impart detrimental effects
on HSCs that echo the results previously discussed. Methotrexate (MTX), a longapproved cancer drug within the antifolate class which inhibits endogenous nucleotide
synthesis, has been well documented to induce oxidative stress within target tissues (9,
202). MTX treatment results in an increase of superoxide production while concurrently
depleting cellular glutathione and total thiol levels by 70%. These MTX mediated
changes in the cellular redox environment are accomplished via inhibition of MnSOD,
GPx, glutathione reductase (GR) and γ-glutamylcysteine synthetase (GCL) (9). While
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chemotherapeutics such as MTX target dividing cells, quiescent HSC populations seem
to remain refractory to MTX treatment even in the face of cell cycle inducers. However,
inhibition of nucleoside transport allows for HSPC sensitization to MTX cytotoxicity
resulting in a loss of HSPC function (5). Although antifolate drugs mainly target DNA
synthesis, their effects on redox management cannot be ignored, particularly in the HSC
population where glutathione metabolism and homeostasis is important. Similarly,
cyclophosphamide, an agent that targets dividing cells via induction of DNA cross
linking, causes a significant amount of reactive oxygen species production measured by
DCF fluorescence in HSPCs. This leads to hematopoietic suppression demonstrated by
loss of HSPC quiescence and function followed by increases in peripheral blood and
splenic progenitor populations (143). This is typified by a significant decrease in the
GSH/GSSG ratio. Interestingly, application of a glutathione disulfide mimetic
significantly decreases the production of ROS and partially rescues the changes in
cellular glutathione (49). This GSSG mimetic also increases the number of HSPCs
depleted by cyclophosphamide treatment and partially rescues HSPC function. Treatment
also rescues cyclophosphamide suppression of antioxidant gene expression, particularly
SOD3 and GPX2 (49).
Perhaps one of the most potent and popular chemotherapeutics approved for treatment of
leukemia’s are the anthracyclines. Of this class, Doxorubicin/Adriamycin (DOX/ADR) is
possibly the most well documented redox stress inducer. DNA intercalation and
inhibition of topoisomerase II is the primary mechanism of DOX induced cytotoxicity in
cancer. However, the ability to act as a redox modifier results from NADPH mediated
formation of a semiquinone structure, which allows for the generation of oxygen radicals,
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hydrogen peroxide, DNA damage, and alterations in bioenergetics (47, 50, 68, 114, 135,
136, 246, 254). Fenton type chemistry may then exacerbate this process, leading to the
generation of hydroxyl radicals. It is no surprise then that the use of anthracyclines such
as doxorubicin is applied to the detriment of normal hematopoiesis (19, 39, 42).
Traditionally, pharmacological doses of DOX induce myelosuppression, cardiac toxicity,
and the enrichment of refractory cancer stem cells through the elevated expression of
multidrug resistant proteins such as MDR1 and MRP1/ABCC1 (19). DOX treatment
specifically suppresses the number of ABCG2+ HSPCs and bone marrow sphere
formation in comparison to vehicle and Paclitaxel controls in vitro. Decreases in
ABCG2+ HSPCs as well as peripheral white blood cells have also been demonstrated in
vivo at doses of 1-5 mg/kg DOX (19). More recently, Mahbub and colleagues discovered
that DOX and etoposide (ETP) can be combined with several different polyphenol
compounds to enhance malignant cell death in both lymphoid and myeloid lineage cancer
models while at the same time protect normal CD34+ and CD133+ HSPC
populations(126, 127). With DOX and ETP in vitro concentrations ranging from 0.1-0.4
µM, combinations of five different polyphenol compounds (Quercetin, Apigenin,
Emodin, Rhein, and Cis-stilbene) all recovered levels of ATP production and Caspase 3
activity when compared to DOX and ETP treatment alone. In these studies, cellular
glutathione levels were identified as a key factor in mediation of protection in
combination treatments (126, 127). Interestingly, quercetin and apigenin, compounds
recognized as mitocan’s (which specifically target mitochondria of cancerous cells) can
bind ANT (adenine nucleotide translocase) of the mitochondrial permeability transition
pore, inhibiting its function and the efflux of mitochondrial ATP (72, 153).
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Redox-based Therapeutic Protection of the HSPC
A precedent for HSPC protection has been established in the past with the use of
granulocyte colony stimulating factor (G-CSF), erythropoietin, and other hematopoietic
stimulants such as pegfilgrastim (Nulasta). These have been used to bolster production of
peripheral blood cells in the face of small molecule chemotherapeutics, such as
cyclophosphamide, as well as antibody based therapies (119). While the use of
antioxidants, such as resveratrol and NAC, in cancer therapeutic regimens has been a
subject of debate, the prospect of protecting normal HSPC function while killing
malignant cells merits investigation and consideration, as the potential impact of
accomplishing both simultaneously cannot be over stated. HSPC protection in the face of
oxidative insult has been accomplished through the upregulation of antioxidant enzyme
function. Furthermore, this protection is actually supported by the induction of redox
stress, ( i.e., the generation of oxido-reductive reactive species that upregulate
endogenous antioxidant machinery). Liposomal delivery of a vector containing an
MnSOD construct protected HSPCs of mice receiving a limiting dose of donor bone
marrow in the face of a 10 Gy total body irradiation (TBI) (134). This protective effect is
enhanced when the MnSOD vector is delivered before the TBI. Protection of the HSPC is
accompanied by a significant decrease in ROS production. Interestingly, HSCs
overexpressing catalase (CAT) and MnSOD performed better in long term competitive
repopulation assays, with CAT outperforming the MnSOD over expressers. Importantly,
the repopulation ability of these subjects was significantly increased after recipients were
exposed to a lower 2 Gy dose of radiation. This indicates that upregulation of antioxidant
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defenses primes HSCs to rebuff subsequent oxidative insult, resulting in an increase in
HSC function (134).
The antioxidant protective effect of upregulated MnSOD in HSPCs can also be achieved
through the application of manganese containing porphyrin compounds (12, 14, 211). A
significant characteristic of these compounds is the stable Mn3+ center and the ability to
accumulate in the mitochondrial fraction (193). Manganese, and iron containing
porphyrins mimicking endogenous SOD function have been successfully utilized for the
protection of bone marrow, among other tissues, against the oxidative challenges of
radiation therapy (12, 31, 210, 211, 234). MnTE-2-PyP5+ (MnTE) has demonstrated
protection of the HSPC in the face of a sub-lethal TBI dose of 6.5 Gy. Administered at a
dose of 6 mg/kg on the day of and for 30 days subsequent to TBI injury, MnTE-2-PyP5+
improved hematopoietic recovery (12, 118, 211). This resulted from improved function
of both hematopoietic stem and progenitor cells compared to control treated mice.
Importantly, MnTE treated HSPCs demonstrated a decrease in senescence induced by
TBI through the downregulation of p16Ink4a expression (161, 185, 231). Pharmacological
protection of both the splenic and bone marrow HSPC compartments from TBI of 7.5 Gy
has also been achieved through the implementation of the flavonoid, baicalein (160).
Both in vitro and in vivo treatment with baicalein resulted in an inhibition of phosphatase
MKP3, ERK activation, nuclear accumulation of NRF2 and an increase in NRF2 target
mRNA (160). These studies indicate that redox active compounds may offer dual
targeting of the NRF2 and MAPK signaling pathways in normal HSPCs, a concept that
may aid redox active therapeutic targeting of malignant HSPC populations over normal
HSPCs.
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Our studies demonstrated similar effects of improved HSPC number and function
generated by overexpression of mitochondrial MnSOD. Our more recent work has further
explored this concept utilizing the MnSOD mimetic MnTnBuOE-2-PyP5+ (MnTnBuOE).
MnTnBuOE treatment in vitro as well as chronic treatment in vivo results in an increase
the HSPC LSK population, similar to MnSODTgH mice (256). Moreover, LSK
populations significantly increase through tertiary bone marrow transplants from donor
cells treated with MnTnBuOE for 16 hours in vitro as well as donor BM from mice
treated at 2 mg/kg/ 3 times per week for a total of 60 days. Not only does MnTnBuOE
increase HSPC function evidenced by long-term transplant studies, MnTnBuOE
treatment significantly improves the recovery of RBC’s and hemoglobin after induced
acute blood loss (256). Although MnTnBuOE is traditionally considered to function as an
antioxidant, due to its MnSOD like activity, we found that MnTnBuOE treatment
decreases mitochondrial function and ATP-linked oxygen consumption within the HSPC
fraction. Concurrently, MnTnBuOE induces mild ROS production, measured by DCF
fluorescence. Here, an increase in DCF fluorescence identifies an increase in general
reactive species. This is presumably due to an increase in hydrogen peroxide production
resulting from the reduction of superoxide by MnTnBuOE. However, because SOD
mimetics are also known to modulate peroxynitrite levels, further study is required to
elucidate the precise ROS resulting from MnTnBuOE treatment. Rather than oxidative
activation of p38 MAPK signaling resulting in cellular senescence and apoptosis as
previously mentioned, MnTnBuOE treatment results in the activation of ETS (E26
Transformation Specific) and NRF2 transcriptional machinery. MnTnBuOE treatment
results in an increase of NRF2 target transcript levels (CAT, MnSOD, GCLC, GCLM,
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Nq01, UPC1, UPC3, and PRDXR1)(256). Western blot analysis of the LSK population
confirms the increase of MnSOD, CAT, GSTp1, and UPC3 protein levels after
MnTnBuOE treatment. These results indicate that MnTnBuOE initially acts as a transient
pro-oxidant ultimately resulting in activation of an antioxidant phenotype that improves
and protects HSPC function. In fact, we found that the HSPC/LSK population has a
significantly higher 2GSH/GSSG ratio as well as an increased ability to remove hydrogen
peroxide in comparison to differentiated myeloid progenitor cells (256).
Protecting or supplementing HSPC function through the upregulation of antioxidant
activity via gene delivery or chemotherapies is demonstrated by the application of
limiting doses of sub-lethal and lethal TBI (12, 75, 118, 134, 161, 185, 231, 256). The
management of NADPH/NADP+ levels has emerged as a critical factor for the protection
of HSPC function. HSPCs express multiple isoforms of the nicotinamide adenine
dinucleotide phosphate oxidases (NOX) that constantly produce ROS (166). TBI causes
DNA damage and double strand breaks leading to the upregulation of the INK4A cell
cycle regulators and HSPC senescence (185, 231). Inhibition of NOX by treatment with
diphenylene iodonium (DPI) resulted in HSPC protection from ROS induced DNA
damage(161). This is similar to the protection achieved by HSPC treatment with MnTE
(118). As previously noted, MnTE treatment protects irradiated HSPC function by
downregulation of p16INK4A, a key player in p38 MAPK induced HSPC senescence.
MnTnBuOE treatment of non-irradiated HSPCs significantly improves HSPC function
through the transient production of ROS and activation of NRF2. This results in
upregulation of not only MnSOD and CAT protein levels, but also results in an increase
NAD(P)H dehydrogenase quinone 1 (NQO1) transcript levels (256). Together, these
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results indicate that the redox management of the NADPH/NADP+ system is critical
HSPC regulation. This also presents the NOX and NADPH dehydrogenases as potential
targets for redox active compounds that include the Mn porphyrins. Other, natural extract
compounds such as apocynin and pumbagin also target the NOX system as well as
modify the cellular redox environment through changing the cellular GSH concentrations
(128). Thus, emerging redox active compounds with the ability to act not only as a mild
antioxidant, but also as a mild pro-oxidant may not only be successful in eradicating
malignant cells, but also may protect normal HSPC function.
These studies further suggest that, contrary to the currently accepted dogma of ROS
effects on long term HSC function, modulation of oxidative challenge to illicit a low to
moderate level of redox stress can actually offer protection by upregulating HSPC
function through NRF2 activation. This is accomplished through functional duality of
redox-cycling compounds (Figure 1.4). For example, MnTnBuOE has the ability to
oxidize superoxide to molecular oxygen in one half reaction while maintaining the same
proclivity for the reduction of superoxide to hydrogen peroxide in another half reaction
(12-14, 210, 211). Redox active compounds can accomplish this by closely mimicking
structure-function characteristics of endogenous enzymes. In the case of MnTnBuOE,
functional mimicry is characterized by the half-wave reduction potential of the
manganese center, which is very close to the potential of MnSOD itself (12-14, 210,
211). Other compounds such as polyphenols and flavonoids can have differential effects
on normal and malignant cells also by targeting anti-oxidant machinery such as
components of GSH metabolism and NRF2 activation discussed later in this review.
Mixed oxido-reductase function of compounds like MnTnBuOE are contrary to
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conventional chemotherapeutics, such as DOX, that can act as oxidizing agents resulting
from metabolic/bioenergetic alteration or interaction with the cellular redox milieu. With
this principal in mind, differences in the basal redox environment between normal and
malignant cells now exposes cancer cells to redox based therapies that offer little harm to
normal HSPCs (Figure 1.5).
Redox Based Therapies Targeting the LSC Redox Environment
The reactive species generated by malignant HSPCs is closely linked to metabolism.
Thus, as malignant HSPCs or LSC’s undergo clonal expansion at an unchecked rate, in
comparison to their normal counterparts, the HSPC redox environment has emerged as an
identifying trait between normal and malignant stem cells (1, 4, 74, 87, 88, 165, 167, 189,
199, 204). Although most cancer drugs were developed to interfere with DNA synthesis,
a number of common therapeutic compound classes, already discussed, do in fact induce
ROS generation. Because the compounds such as DOX, MTX, ETP, cyclophosphamide,
and cytarabine are all administered to the peril of the normal HSPC, new methods of
employment must be considered. Transient, low dose regimens and/or combination
treatments present viable options for safer usage, and several studies within the last 5
years have begun to explore these options and are reviewed here.
As previously discussed, the glutathione system has emerged as a key regulator of HSPC
function and as such may be targeted by redox active compounds for the treatment of
hematopoietic malignancies. BSO is a potent inhibitor of glutathione synthesis and as
previously discussed has been used to demonstrate stem cell exhaustion. For this reason,
clinical utilization of BSO has some potential downfalls. However, Tagde and colleagues
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have shown the effective combination of melphalan (L-PAM) and BSO in preclinical
models of multiple myeloma. High GSH levels are indicative of an aggressive multiple
myeloma (MM) relapse phenotype that may be resistant to L-PAM, depletion of GSH
with BSO sensitizes 9 MM cell lines and primary MM samples to L-PAM treatment
(203). This potentiation is blocked by treatment with NAC, which does not change
cellular GSH concentrations. The combination of BSO and L-PAM results in DNA strand
breaks, mitochondrial dysfunction, and activation of apoptosis. This combination was
also successful in depleting GSH and inducing engraftment suppression within 3 human
MM xenograft models (203).
The regulation of antioxidant enzyme expression within LSC’s differs vs their normal
counter parts, but these defense enzymes also differ between types of hematopoietic
malignancies. For example, CD34+ cells isolated from acute myeloid leukemia (AML)
patients express low levels of SOD2 and CAT and higher levels of GCLC, GCLM,
GPX1, and TXN than their normal CD34+ counterparts (163). SOD2 and CAT levels
vary among other cancers within the myeloid lineage (217, 253). However, elevated
expression of glutathione metabolism enzymes highlight the importance of glutathione
regulation within malignant HSPC populations, just as in normal HSPCs. Indeed the
GSH/GSSG system has successfully been targeted for therapy using several compounds
that contain α,β-unsaturated-γ-lactone groups or have strong electrophilic character and
have the potential to react with free thiol groups: parthenolide (PTL) and piperlongumine
(PLM) (163). Both of these compounds preferentially deplete cellular glutathione levels
in CD34+ malignant cells compared to normal counterparts. Additionally, PTL and PLM
treated normal HSPCs demonstrate some degree of GSH/GSSG recovery, whereas the
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malignant cells do not, offering protection of normal HSPCs and cytotoxic effects in
malignant HSPCs. The result of this GSH depletion is an increase in cleaved caspase 3
and cleaved PARP leading to a significant induction of LSC cell death compared to
normal CD34+ HSPCs. Ultimately PTL was found to actually bind several enzymes
involved with glutathione synthesis including GCLC and GCLM (163). PTL also
exhibited a synergistic effect when paired with low doses of cytarabine and idarubicin
(79).
PTL and several other natural compounds, including polyphenol and flavonoids, have
demonstrated potential therapeutic efficacy in chronic myelogenous and lymphocytic
leukemias. For example, Wu and colleagues evaluated the effects of 27 different
compounds that include: α-β-unsaturated carbonyls, sulfhydryl reactive metals,
isothiocyanates, polyphenols, and flavones on NRF2 activation and cytotoxicity in
PBMCs (peripheral blood mononuclear cells) isolated from normal and CLL patients
(236). Through the analysis of the NRF2 target HO-1 (heme oxygenase-1) and NRF2
protein levels, they first found that NRF2 activity was higher in PBMCs from CLL
patients compared to their normal controls. In all, 6 α-β unsaturated carbonyls, 3 arsenic
containing sulfhydryl reactive metal, 2 isothiocyanates, 2 flavones, and 5 polyphenol
compounds were able to activate NRF2 in a FRET β-lactamase based reporter assay in
HepG2 cells (236). Cytotoxicity evaluation via MTT analysis showed that several α-βunsaturated carbonyls, sulfhydryl reactive metals, isothiocyanates, and flavones were
selectively cytotoxic to primary CLL samples compared to their normal counter parts. In
the case of PTL and ethacrynic acid (EA), loss of α-β unsaturated carbonyl groups
diminished NRF2 activation and CLL selective cytotoxicity (236).
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As discussed previously, Tsai and colleagues were able to utilize the Nrf2-/- mouse model
to demonstrate a downregulation of homing and chemotaxis of HSPC’s associated with
the loss of CXCR4 (219). Similarly, an increase in CXCR4 expression resulting from an
upregulation of CXCL12 results in DOX resistant K562 CML cells (K562/ADM) (232).
This is characterized by an increase in PI3K activation and NF-kB translocation to the
nucleus; whereas, CXCR4 siRNA downregulates PI3K/AKT, and IKKα activation
sensitizing K562/ADM cells to DOX treatment demonstrated by an inhibition of cell
growth and increase in apoptosis (232). Both in vitro and in vivo, treatment with oroxylin
A, a monoflavonoid, targets leukemic/ADM cells with low off target toxicity by
increasing apoptosis via downregulation of CXCR4 expression (232). Taken together,
these results suggest that compounds such as polyphenols or flavonoids may be able to
target the malignant cell redox environment through the manipulation of the NRF2
pathway. As discussed earlier, the flavone baicalein offers protection of splenic and bone
marrow HSPC from TBI through ERK and NRF2 activation (160). However, in the
malignant K562 CML cells treatment with both baicalein and baicalin result in an
increase in NOTCH-1 activation followed by an increase in Hes-1, cyclin D1, Hey-1, and
Hey-2 mRNA levels (229). This highlights the potential for the redox mediated
protection of normal tissues with simultaneous targeting of cancer cell populations.
Additionally, treatment of K562 cells with baicalin and baicalein resulted in an increase
of cells in G0/G1 phase as well as a decrease of cells entering S-phase and G2/M phase,
whereas treatment with baicalein only resulted in a decrease of cells in G2/M phase (229).
This could be due to the metabolic conversion of baicalin to baicalein through the
cleavage of a glyosidic moiety. Interestingly, both compounds inhibited K562 colony
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formation in soft agar assays (229). Again, this highlights the ability of redox active
compounds to selectively target the malignant cellular redox environment, while at the
same time, offer protection to normal HSPC populations.
Glutathione homeostasis is also targeted by synergistic combination treatments of
lymphoid and myeloid cell lines with polyphenol compounds and DOX or ETP (126,
127, 252). Quercetin, apigenin, emodin, rhein, and cis-stilbene all had synergistic effects
with DOX and ETP that resulted in cytotoxicity within CCRF-CEM and Jurkat malignant
lymphoid cell lines. Quercetin and apigenin, however, were the only polyphenols that
demonstrated synergistic effects with DOX and ETP in THP-1 and KG-1a malignant
myeloid cell lines. All synergistic effects were closely associated with a decrease of
cellular GSH, a decrease of ATP production and activation of the apoptosis cascade (126,
127). Of note, the lymphoid lineage cell lines being most sensitive to this redox based
combination treatment actually demonstrated the lowest basal levels of GSH, indicating
that lymphoid cancers may be excellent targets for redox based therapies. Other examples
of polyphenol induction of LSC cytotoxicity include the use of Nispex, a polyphenol
mixture that is mainly comprised of quercetin, quercitroside, avicularin and oleandrin.
This mixture has been proven effective against the AML/HL-60 cell line both in vivo and
in a xenograft in vivo model (76, 77, 243).
The HL-60 cell line is one of the earliest malignant promyelocytic leukemia cell lines
used for the elucidation of chemotherapeutic mechanisms. DOX treatment of HL-60 cells
results in the activation of caspases 3, 8, and 9 as well as DNA fragmentation (201). The
development of the HL-60/ADR (DOX resistant) cell line has led to the implementation
of alternative therapies that include DOX. For example, pre-treatment with a sub-lethal
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dose of DOX and subsequent combination with TRAIL, a member of the TNF family,
induces cytotoxicity in the parental and HL-60/ADR cell lines, indicating that DOX
induced redox signaling even in drug resistant tumor types (105). This occurs through the
depolarization of the mitochondrial membrane and increased levels of caspase 9 and
Apaf-1 from the activation of mitochondrial type II apoptosis pathway (105).
Importantly, HL-60 cells have demonstrated sensitivity to other, more basic redox active
compounds such as exogenous hydrogen peroxide and the nitroxide compound, tempol
(150). HL-60 cells demonstrate significant sensitivity to H2O2 induced cell death
measured by apoptotic markers at concentrations as low as 5 µM, whereas normal bone
marrow and mononuclear cells isolated from cord blood remain resistant to cell death.
Primitive populations isolated from normal control were not affected by H2O2 treatment,
yet CD34+ populations isolated from the HL-60 pool were significantly reduced without
differentiation at all H2O2 concentrations evaluated. The authors continued to identify
AKT as a potential mediator of H2O2 induced cell death within progenitor populations of
HL-60 cells (150). Tempol treatment of HL-60 cells results in a p53 independent
upregulation of p21, indicating that peroxide generating and nitroxide compounds may be
promising alternative therapies for chemo-resistant tumor types (72, 150).
MnSOD has been widely discussed as a tumor suppressor for many years, and just as the
roles of glutathione homeostasis and catalase activity play important parts of normal and
malignant HSPC treatment, MnSOD has also been recently demonstrated as a potential
therapeutic specific to malignant HSCs (152, 255). A phenotypic trait that separates
HSPCs from LSC’s is the differential expression of various surface markers, such as
CD33 and CD123 (167). For example, some LSC populations exhibit high levels of
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CD123 or IL-3R expression whereas normal HSC populations do not (167). This has led
to a targeted approach for the delivery of MnSOD as a tumor suppressor. Much like the
liposomal delivery of MnSOD previously discussed in normal HSPCs, Li and colleagues
utilized CD123 for the targeted delivery of adenoviral particles carrying the MnSOD
gene. Adenoviral delivery of MnSOD induced dose dependent cytotoxicity in HL-60 and
KG-1 malignant myeloid cell lines (117). Upon infection, cytotoxicity is accompanied by
increases in cleaved caspases 7 and 9 as well as increases in cleaved PARP indicating
mitochondrial activation of apoptosis. Additionally, delivery of MnSOD to xenografted
HL-60 cells prolonged survival in mice (117). Similar results were seen via treatment of
murine thymic lymphoma cells. Here, Jaramillo and colleagues found that elevated
expression of MnSOD increased cellular hydrogen peroxide, sensitizing WEHI7.2 cells
to glucocorticoid and hydrogen peroxide induced apoptosis. This result was recapitulated
with the application of MnTE. Although application of MnTE can in some cases produce
peroxide, sensitization of WEHI7.2 cells may occur through another mechanism, such as
the oxidation of NF-kB (93). Additionally, MnTE combination treatment with
cyclophosphamide inhibited cell growth. No sensitization of WEHI7.2 cells was
demonstrated in a combination of MnTE and DOX; however, MnTE addition protected
cardiomyocytes from DOX induced injury (93). These findings have large implications
for the future of leukemia drug development: delivery of MnSOD to normal HSPC
populations either by genetic overexpression or treatment with an SOD2 mimetic
promotes HSPC function while ectopic MnSOD expression or Mn porphyrin (MnP)
treatment in leukemia cell populations clearly induces cell death (93, 117, 118, 134, 256).
Furthermore, MnP function within malignant populations may be enhanced by the
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presence of other biologically relevant redox active compounds and/or proteins. For
example, Ferrer-Sueta and colleagues have shown that MnPs may be reduced by enzymes
such as xanthine oxidase and complex I and II of the mitochondrial electron transport
chain (59). This reduction shown in submitochondrial particles allows for catalytic redox
cycling and reduction of peroxynitrite, offering mitochondrial protection against
peroxynitirite formation and damage (59, 225). Additionally, the combination of MnP’s
with vitamin C has a promising outlook. Vitamin C itself has demonstrated a protective
effect against oxidative insult within HL-60 cells (73). However, varying concentrations
of vitamin C in combination with Mn porphyrins may be effective. Although this
combination has not been evaluated in HSPC or LSC populations, vitamin C has been
shown to sensitize pancreatic and breast cancer cell populations through metabolic
alterations to the cellular redox environment and production of species such as peroxides
(51, 212, 220). Furthermore, MnP combination with vitamin C has demonstrated
significant effects on the malignant cell redox environment, primarily through the
generation of hydrogen peroxide, within prostate and breast cancer, as well as
glioblastoma cells (55, 212, 250, 257). This strategy is supported by the finding that
exogenous H2O2 kills primitive LSC’s while leaving normal HSPC populations unharmed
(150). This indicates that redox active compounds such as MnSOD mimetics, themselves
or in combination with other redox active drugs, may be able to modulate redox levels
that support healthy HSPC function leading to the safe eradication of LSC’s from the
hematopoietic compartment.
Perhaps one of the most primitive and aggressive of all hematopoietic cancers are
CML’s. CML patients in blast crisis undergo rapid clonal expansion of progenitor cell
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compartments and are often resistant to TKI therapies due to altered expression of the
BCR-Abl fusion gene (41, 83). Redox based therapies, however, offer potential solutions
to refractory disease. Treatment of the KBM5 and the KBM5-T315I TKI resistant CML
cell line with ROS inducers such as adaphostin or β-phenylethyl isothiocyanate (PEITC)
results in complete inhibition of CML cell growth within cell lines and primary samples
(35, 154, 217, 253). The cytoxicity is based on these ROS inducers ability to modify the
redox environment of the CML cell that results in the oxidative modification and
subsequent cleavage of the BCR-ABL protein. The modification of the redox milieu is
caused by a sharp depletion of cellular glutathione. Decreases in GSH, BCR-ABL
cleavage and cytotoxic effects are reversed by the pre-treatment of CML cells with NAC.
Similar effects of BCR-ABL degradation are caused by treatment with BSO. PEITC
induced cytotoxicity is also observed in primary CML patient samples drawn from
individuals who display both imatinib sensitivity and resistance (253).
Similar studies have been conducted in the CD34+ K562 CML cell line. The K562 line is
a BCR-ABL+ cell line that demonstrates resistance to imatinib. However, K562 cells are
sensitized to imatinib by co-treatment with simvastatin, a known nitric oxide producer
(36). The sensitization of K562 cells to this combination treatment is rescued by pretreatment with NAC, implying that the production of reactive oxygen species allows for
successful treatment. This may very well proceed through the depletion of cellular
glutathione subsequent to the production of peroxynitrite (36). More recently, a
combination treatment of DOX and polyphenol extract from V. album rescued K562 cells
from G2/M arrest by expression of cyclins B1 and D1. This resulted in the activation of
apoptosis and sensitization of K562 cells to DOX treatment (196). Elucidation of redox
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modifiers that can impact primitive and resistant malignant populations are clearing the
way for emerging combination treatments, allowing for the use of sub-toxic doses of
classic chemotherapeutics that, originally, were detrimental to the patient hematopoietic
compartment. These findings highlight the important ability of redox modifiers to provide
new solutions for refractory diseases, ultimately improving outcomes for patients with a
poor prognosis.
Redox Based Therapies Targeting LSC Metabolism
Expertly reviewed by Pollyea and Jordan, the LSC redox environment can be specifically
targeted through differential metabolic profiles between HSPCs and LSC’s (167).
Potential targets of LSC mitochondrial induced apoptosis are IKK2 (IKB Kinase 2) and
nuclear factor-κB (NF-kB) (64). Inhibition of NF-kB activation results in mitochondrial
dysfunction, rupture and cell death. Importantly, NF-kB demonstrates constitutive
activation in AML and has been used to characterize LSC populations (21, 142). As
demonstrated in the combination treatment of TRAIL and DOX for refractory AML cells,
inhibition of NF-kB with small molecules such as JSH-23 or AS602868, also sensitizes
LSC’s to treatment with TRAIL (56, 64, 208). As mentioned throughout this review,
targeting glutathione metabolism may also occur in the mitochondria, separating the LSC
population apart from normal HSPC populations. Recently, however, more exciting
discoveries have come to light. Several recent studies have identified the isocitrate
dehydrogenases as redox active targets for cancer therapies. For example, downregulation
of IDH1 may sensitize cells to hydrogen peroxide production. Conversely, over
production of the oxidative metabolite 2-hydroxyglutarate sensitizes LSC’s to BCL-2
downregulation (34, 61, 112, 167). The overproduction of 2-hydroxyglutarate, stemming
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from mutations in the isocitrate dehydrogenase enzymes may cause epigenetic changes
that can lead to leukemogenesis (34, 61, 111, 112, 167, 190). Thus, from these studies we
may learn of redox driven epigenetic events that initialize HSPC transformation in the
bone marrow niche. Additionally, we have found that the MnTnBuOE porphyrins are
excellent candidates for the alteration of HSPC and LSC mitochondrial function.
Treatment of HSPCs with MnTnBuOE results in a decrease of mitochondrial function, an
increase in antioxidant defense enzyme levels, and an increase in uncoupling protein
expression eventually offering protection of HSPCs (256). Moreover, as previous
evidence has suggested, these same changes may have cytotoxic effects in LSC
populations.
Targeting the NADPH Oxidase System
As previously mentioned, normal HSPC irradiation produces a phenotype of HSPC
exhaustion resulting from DNA damage and the upregulation of cell cycle inhibitor
proteins leading to HSPC senescence (185, 231). This exhaustion can be protected
against by treatment with redox active compounds (93, 118, 134, 256). The principal
mediator of these effects is the ROS produced by the NOX enzymes, implicating NOX
enzymes as potential redox based therapeutic target for leukemia’s (82, 94, 129, 166,
197). Aggressive sub-populations of AML can be identified by internal tandem
duplication of the FMS-like tyrosine kinase (FLT3-ITD) (176, 197). This population has
elevated levels of DNA damage and ROS production. However, recent studies,
particularly those demonstrating that Nox4-/- mice are resistant to a FLT3-ITD mediated
induction of a myeloproliferative disorder (MPD) phenotype, elucidate NOX as a driving
factor in the generation or propagation of the LSC (94). These studies further suggest that
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redox based therapies targeting NOX produced ROS may simultaneously be effective in
the treatment of LSC’s. Inhibition of the FLT3-ITD signaling via PCK412 treatment
results in decreased STAT5 signaling and the downregulation of the NOX subunit
p22phox (235). This and the inhibition of NOX via diphenylene iodonium (DPI) or
VAS2870 treatment led to a decrease in DNA damage as well as a decrease in hydrogen
peroxide production in the cytosol and nucleus of AML blast cells. Both culture models
and primary patient HSCs that demonstrate elevated ROS production by NOX, have
depleted GSH levels, and diminished antioxidant capabilities (197, 235). These facets
promote the growth of LSC population over their normal CD34+ counterparts, and this
growth advantage is also mediated through loss of response to the p38 MAPK signaling
pathway. Taken together, these results show that just as normal HSPCs undergo
exhaustion in response to ROS mediated MAPK signaling, malignant LSC populations
are propagated through NOX induced ROS and loss of their normal p38 MAPK response
that limits HSPC pools. In addition to NOX inhibitors, this presents another therapeutic
window for the Mn porphyrins in leukemia therapeutic regimens. The redox-active
MnTnBuOE and MnTE are able to modulate the cellular redox environment offering
control over the p38 MAPK, NRF2, and NOX/NQO1 systems that may protect normal
HSPCs while driving malignant cells to activate cell senescence mechanisms (Figure
1.5).
Epigenetic Considerations in LSC Redox Treatments
Targeting epigenetic characteristics have also become a successful avenue of treatment
for many hematopoietic disorders including AML, myelodysplastic syndrome (MDS),
and CML. Several cytogenetic abnormalities have become very prominent across the
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leukemias, particularly those involving fusion of MLL/ENL and HOXA and NUP98
genes within AML, BCR-ABL in CML and ALL, and Del5q syndrome in MDS (17, 18,
26, 36, 102, 113, 184, 190, 196, 207). Aberrant DNA methylation patterns have widely
been recognized for the characterization of hematopoietic disorders within both the
myeloid and lymphoid lineage (62, 66, 71, 89, 98). As patient populations grow
increasingly resistant to therapies, methyl transferase or demethylase inhibitors such as
the azacytidines and histone deacetylase inhibitors have been developed (186, 190). Even
still, many patient populations demonstrate resistance to epigenetic therapies. As with
resistant CML’s, there does seem to be a role for redox active compounds in combination
treatments that result in sensitization to epigenetic treatments. Recently, inhibition of
LSD1 demethylase with trans-2-phenylcyclopropylamine (TCP) combined with all-transretinoic acid (ATRA) treatment induced sensitivity in several AML models. This was
demonstrated by decreased AML engraftment in vivo as well as an increase in the
expression of differentiation markers such as CD11b (180). This has potential redox
implications as ATRA has been known to induce ROS mediated embryonic stem cell
death (30). Additionally, ATRA has been identified as a NRF2 inhibitor and has
potentiated arsenic trioxide toxicity in human AML cells (224, 230). Combination
treatment in multiple myeloma with the histone deacetylase inhibitor PXD101 and
bortezomib induces cell death in primary CD138+ MM cells, but not normal bone marrow
populations (58). These effects are driven by activation of caspases 3, 8, and 9 with
coordinate activation of p53 and the p38 MAPK pathway; all of which can be blocked
with NAC treatment (45, 58, 200, 251). Finally, the methyltransferase inhibitor 3deazaneplanocin (DZNep) inhibits the polycomb-repressive complex-2 (PRC2) through
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upregulation of thioredoxin interacting protein (TXNIP). TXNIP activity then results in
TXN inhibition and a subsequent increase in oxidative stress that may not be a direct
result of TXNIP mediated inhibition of TXN itself. This ultimately results in apoptotic
signaling within AML culture lines as well as primary samples (258). This also identifies
DZNep as a potential therapy for CML (183, 244). The discovery of TXNIP
downregulation in AML’s and the identification of PRC2/EZH2 as a target for redox
based therapies is an exciting advancement (183, 244). Recently the Txnip-/- model has
identified TXNIP as a crucial regulator of normal LT-HSC function (96, 101). Txnip -/mice undergo HSPC exhaustion that is characterized by loss of repopulation capacity,
increased Wnt signaling, decrease in p21 expression, and loss of CXCL12 activity within
the bone marrow niche (96). Loss of TXNIP, as has been demonstrated in AML’s, results
in an advanced aging phenotype in which HSC exhaustion and bone marrow failure
occurs through activation of the p53 and p38 MAPK pathway and induction of cell cycle
regulators (258). Together, these results demonstrate that the Txnip-/- phenotype closely
resembles hematopoietic phenotypes characterized by pharmacological induction of
redox stress or those generated by the selection of ROS high populations. These studies
highlight the potential redox targeting pathways of normal HSPCs use for maintenance
within malignant populations. This supports the employment of ROS and redox
modulation for the successful development of cancer therapies, which are highlighted by
the protection of normal tissues (Figure 1.5). We have summarized the redox active
compounds as they have been cited and discussed throughout this review to highlight
potential areas of therapeutic development that may safely and successfully target
malignant populations in the future (Table 1.1).
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Summary
In the past, the limited, primitive and quiescent state of HSPCs has made it difficult to
meaningfully evaluate the impacts of redox modification in normal and malignant
HSPCs. In the last 10 years, we have begun to significantly evaluate and realize the
important impact that management of the HSPC redox environment has on normal
hematopoiesis and overall patient outcome. We now know that the HSPC redox
environment can be manipulated by redox active compounds to protect and improve
HSPC function while still creating stress conditions that may differentially target
malignant LSCs. This may be accomplished through combination therapies utilizing low
dose chemotherapeutics and the implementation of a single redox cycler. To this purpose,
several crucial pathways, such as FOXO, ATM, NRF2, NOX, NF-kB and p38 MAPKs,
have emerged as critical HSPC redox regulators.
Through the years, there has been some debate over the importance of an impact of GSH
homeostasis in the management of cellular redox environments and the treatment of
cancers (63). However, within the HSPC compartment, the management of GSH/GSSG
levels appears to be indispensable. Accurate measurement of cellular GSH and GSSG
concentrations obviously provides insight to the mechanistic underpinnings of drug
activity as previously discussed, and new methods of quantitation have emerged allowing
for GSH measurement in HSPC populations (29, 195). These studies may also aid in the
identification of therapeutics not previously thought to be redox active. For example,
lenalidomide (LEN) has been used for the treatment of several hematopoietic diseases
(130, 184, 207). This compound, an immunomodulatory agent which can aid in the
restoration of normal hematopoiesis, has demonstrated the redox-mediated activation of
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AP-1 signaling in multiple myeloma treatment (43). Subsequently, we found that LEN
can deplete cellular GSH levels in a myelodysplastic syndrome (MDS) model at a level
and rate similar to DOX (29). This now opens both LEN and MDS to consideration for
redox based therapies. Additionally, our previous work has demonstrated that modulation
of MRP1 expression dictates cellular GSH/GSSG concentrations. Most notably, an
increase in HSPC GSH concentrations are demonstrated in the Mrp1-/- mouse model, in
which loss of MRP1 results in an increase in HSPC function. These results are
demonstrated by colony formation assays as well as in vivo serial transplantation
experiments. Improvements in WT HSPC function, compared to the Mrp1-/- can also be
recapitulated with the addition of NAC (170). This indicates that ABC transporter
inhibitors may have a role in the development of leukemia therapies that protect the
HSPC compartment. Moreover, GSH and GSSG levels appear to be a potential biomarker
for the redox based therapy candidacy. We have previously found that peripheral
leukocytes isolated from AML patients contain significantly higher cellular GSH levels,
resulting in a significant difference in the 2GSH/GSSG ratio between patients and healthy
donors (29). These elevated GSH levels may be the result of an increase in reactive
oxygen species produced by malignant cells, relative to healthy cells. Redox active
therapies must then be able to overcome the increased redox buffer capacity
demonstrated in malignant cells in order elicit a desired therapeutic effect. Thus, the
2GSH-GSSG ratio may not only be a marker for disease, but serve as an indicator for
redox based therapies. Because the cellular redox potential can be calculated based on the
2GSH/GSSG ratio, we may be able to establish limits of HSPC/LSC redox potentials in
which we know certain redox based therapies will be efficacious (109, 178). In the future,
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evaluation of patient cellular redox potentials across diseases (CML, AML, ALL etc.)
may allow for the prediction of response of disease states to specific redox based
therapies.
The focus of these principles should expand to include a better understanding of other
factors affecting the HSPC redox environment, such as thioredoxin activity and the
function of TXNIP. Thioredoxin interacting protein has recently been identified as an
important regulator of the HSPC, where loss results in p38 activation and LT-HSC
exhaustion (96). If this occurs through NRF2 regulation, TXNIP may emerge as a
druggable target for the treatment of hematopoietic malignancies. Additionally,
cytogenetic abnormalities, such as chromosomal rearrangements and deletions, have been
well documented throughout the hematopoietic diseases, yet major changes in epigenetic
programming remain unclear. For example, TXNIP studies involving DNA methylation
status indicate that future efforts must focus on the impact that redox active compounds
have on the epigenetic regulation of the normal HSPC as well as the malignant LSC.
Redox evaluation of epigenetic changes in hematopoietic malignancies, such as those
demonstrated by the isocitrate dehydrogenase enzymes (IDH1/2), may provide valuable
insight to potential initiating events that drive LSC propagation (34, 61, 108, 111, 190).
This may provide avenues for new genetic based therapies that utilize the manipulation of
the LSC redox environment.
Redox modifiers and redox cycling drugs should be used to elucidate the impact of
signaling pathways contributing to malignant HSPC expansion. For example, subpopulations of aggressive hematopoietic malignancies express several isoforms of the
NOX family, as compared to limited NOX expression in normal HSCs (82, 94, 129).
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However, in normal HSPCs, increased NOX expression and activity results in
.
overproduction of ROS (O2 -, H2O2) leading to the activation p38 MAPK’s, which results

in the upregulation of cell cycle regulators. It is unclear if constitutive NOX activity in
malignant populations leads to the loss of AKT and p38 MAPK regulation over LSC
expansion or if components within, such as the AP-1 family of transcription factors,
maybe targeted for redox-regulation by redox active compounds to regain control of
progenitor compartments undergoing clonal expansion (Figure 1.5). These aspects have
the potential to improve redox based therapies, providing new directions for safe,
effective treatments.
Throughout the work presented here, we focus on the evaluation of the normal and
malignant redox state and examine response to a novel redox active therapeutic in both
normal and malignant populations. We present the development of novel methods for the
evaluation of the HSC redox state. The development and validation of a sensitive and
robust LC-MS/MS method that utilizes the simultaneous quantitation of reduced and
oxidized forms of glutathione is described. With this method we are able to show new
insights into the hematopoietic stem cell redox state within very primitive and small HSC
populations. Furthermore, we show the versatility of this method in the presence of
chemotherapeutics and can use these data to evaluate effects on the cellular redox state
within malignant populations. We further utilize this sensitive methodology to evaluate
the cellular redox state in the face of a novel redox active therapeutic MnTnBuOE-2PyP5+ (MnP). We show that this mimic of manganese superoxide dismutase has similar
effects on the cellular redox state within normal and malignant hematopoietic populations
and examine the effects of H2O2 signaling on the cellular redox state as well as
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transcriptional signal transduction. Through this approach we identify the AP-1
transcription factor JunB as a potential therapeutic target of MnP and evaluate
mechanistic control of JunB signaling through redox regulation within a myelodysplastic
cellular model. We conclude with an evaluation of MnP cytotoxicity within several
leukemic models and the probable redox factors that contribute to MnP sensitivity. These
studies result in the elucidation of chemoresistant factors within the cellular redox milieu
that may modulate MnP toxicity. Notably, the development of the LC-MS/MS
methodology described in chapter two contribute to the observation that the management
of glutathione metabolism may significantly contribute to the development of
chemoresistance within malignant populations, particularly through recycling of oxidized
glutathione via glutathione reductase. The overall findings described here highlight the
evaluation of redox states within small hematopoietic populations and how differences
within cellular redox states may be therapeutically targeted to accomplish the protection
of normal cellular function while simultaneously targeting malignant cell population for
safe eradication.

37

Figure 1.1 Hierarchy of the hematopoietic compartment
The bone marrow compartment contains a complex and highly regulated hierarchy of cell
types tasked with maintaining the production and balance of all cells in the blood system.
Beginning with the most primitive CD34+ LT-HSCs, the ability to self-renew and differentiate
to downstream phenotypes defines the LT-HSC pool with a decreased capacity for self-renewal
as differentiation occurs. From the MPP pool, both lymphoid and myeloid cell types develop
and eventually differentiate into terminal effector cell types seen in the periphery.
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Figure 1.2 Redox active compounds in the bone marrow niche
The bone marrow compartment demonstrates oxygen concentrations that range from 1%
(furthest from the blood supply) to 7% (closest to the blood supply). Low oxygen
concentrations has been referenced as a factor contributing to the protection and
quiescence of HSCs. However, upon transformation, LSCs may demonstrate increased
levels of metabolism and ROS levels, while maintaining a lower antioxidant capacity
than their downstream progeny. This difference, a product of the oxygen environment,
may allow for a differential redox insult and targeting of LSCs over normal HSCs driven
by the introduction of a redox active compound.
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Figure 1.3 Transformation of the HSC/LSC redox environment
Normal and malignant HSC’s demonstrate differences in the regulation and management
of the antioxidant system. Normal HSC’s express higher levels of primary antioxidant
enzymes SOD and CAT. Malignant HSC’s are subject to elevated levels of ROS
produced by NOX enzyme and rely on higher cellular concentrations of GSH as well as
the GSH metabolic system to manage the malignant HSC redox state.
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Figure 1.4 ROS inducers in the HSC
A schematic diagram demonstrates the differential effect and graded response of HSC’s to
various redox active compounds and ROS inducers. Normal hematopoiesis is characterized
by primitive LT-HSC’s that have the ability to self-renew and differentiate into any other cell
type. As differentiation occurs, progenitor cell types lose their ability to self-renew. This
process is accelerated in the presence of potent ROS inducers such as conventional
chemotherapeutic agents and ionizing radiation. Response to these stimuli results in DNA
damage response and activation of signaling that results in the upregulation of cellular
senescence and apoptosis. New evidence now suggests that mild ROS inducers have an
opposite effect, where generation of a mild ROS milieu results in the activation of antioxidant
defense pathways leading to an improvement in HSC function. The result is a graded response
to different levels of ROS stimulant that leads to variations of HSC function and either
exhaustion or strengthening of the hematopoietic niche.
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Figure 1.5 Differential redox signaling in the HSC vs LSC
The pro-survival response of normal HSC’s to mild pro-oxidants has led to the concept
of differential response to redox cycling compounds between normal and malignant
HSC’s. Redox active compounds will use the normal levels of ROS produced by
healthy HSC’s to activate an antioxidant response leading to increased proliferation
and HSC function. Conversely, LSC’s perpetually produce elevated levels of
superoxide via aberrant constitutive enzyme activity that can be used by redox active
compounds to produce second messenger ROS such as hydrogen peroxide. This may
lead to LSC senescence and death. The theoretical result is the protection of normal
HSC function with simultaneous cytotoxic, anticancer affects in the LSC population.
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Table 1.1. Summary of redox active
therapeutics
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The table above summarizes the redox active compounds that have been discussed throughout this review as well as their effects
within their indicated disease states and normal HSPC populations where applicable. This dual application highlights the potential
for selective targeting of malignant populations while offering protection to normal HSPCs for many redox active compounds
discussed and cited within this dissertation.

Chapter Two: Characterizing the Hematopoietic Redox State Through
Simultaneous Quantitation of Oxidized and Reduced Glutathione via LC-MS/MS:
An insight into the redox state of hematopoietic stem cells

Introduction:
Glutathione, γ-L-glutamyl-L-cysteinylglycine, (GSH) is an endogenous tripeptide
involved in many cellular processes including apoptosis, cellular detoxification, and
redox signaling (122, 123). Currently, GSH is considered a major cellular reducing agent.
Intracellular concentrations are high, reported to range from 0.5-10 mM, that aids in
protection from ROS mediated injury (3, 103, 124). GSH/GSSG homeostasis is tightly
regulated with depletion or oxidation of the cellular GSH pool leading to the activation of
anti-oxidant signaling pathways, gene transcription, and GSH synthesis accomplished via
glutamate-cysteine ligase (GCL) activity. Oxidizing cellular conditions lead to the
heterodimerization of the GCL subunits, GCLC (GCL catalytic subunit) and GCLM
(GCL modifier subunit) (10, 247), which results in increased GCL activity. GSH activity
is subsequently regulated via cycling the cysteinyl thiol (pKa= 8.9) through oxidized and
reduced states. GSH-mediated cellular detoxification may be accomplished by the direct
conjugation of GSH xenobiotics and other endogenously produced small molecules via
glutathione-S-transferase (GST) activity or through the action of glutathione peroxidase
(GPx), which reduces hydrogen peroxide while GSH is co-oxidized to its disulfide form
(GSSG) (10, 122, 123, 192). Additionally, GSH may reversibly modulate cellular redox
signaling via direct glutathionylation of thiol groups within redox sensitive signaling
proteins. This post-translational modification may also protect thiol groups within redox
sensitive signaling proteins from permanent modification under oxidizing conditions (46,
69). Similarly, GSH functions to protect mitochondrial 1-Cys peroxiredoxins from
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damaging oxidation as the resolving thiol group in thioredoxin-catalyzed peroxidase
activity in Saccharomyces cerevisiae (162). These functions and aspects of GSH
homeostasis demonstrate the importance of the GSH/GSSG redox pair in the
maintenance of the cellular redox state.
The cellular redox state is commonly characterized by examining the ratio of
reduced to oxidized species within cellular redox pairs. High intracellular concentrations
and redox buffer capacity makes this especially true of the GSH/GSSG redox couple (7,
109, 123, 178). Biochemically, GSH and GSSG may be thought of as components of an
electrochemical half-cell in which the flux of single electron transfers can be quantified
by their electrical potential or electromotive force, characterizing the proclivity of the
GSH/GSSG pair to donate or accept electrons in varying redox states. As a result,
defining the individual absolute cellular concentrations of GSH and GSSG and applying
these concentrations, along with measured values for intracellular pH (pHi) and cellular
volume, to the Nernst equation allows for a more specific analysis of the 2GSH/GSSG
redox state, the electrical half-cell reduction potential (Ehc) (109, 178). Although living
biological systems never rest at a state of equilibrium, characterization of the
2GSH/GSSG reduction potential provides a practical snapshot of cellular redox balance
(63, 178). Furthermore, evaluation of the 2GSH/GSSG Ehc is a strong indicator of the
existing redox state of thiol-containing signaling proteins regulated by glutathione.
The cellular GSH/GSSG ratio is characterized by the equilibrium half-cell
reaction of glutathione species resulting in the synthesis of two moles of GSH from the
reduction of one mole of GSSG, thus the glutathione based redox state is dependent on
cellular GSH concentrations (109, 178). Alternatively, the individual concentrations of
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GSH and GSSG may be considered when characterizing small dynamic changes in the
cellular redox state over time. Consequently, an effective evaluation of the glutathione
based redox state requires a sensitive and accurate method for the quantitation of absolute
concentrations for both GSH and GSSG. This is particularly important for evaluation of
the cellular redox state within hematopoietic malignancies manifesting in hematopoietic
stem-progenitor cells (HSPC’s), a tissue that has inherently limited availability for study
in vivo. For example, in our experience, purification of murine bone marrow typically
results in the isolation of approximately 20,000 HSPC’s from a single animal that
demonstrate the Lin- , Sca-1+, c-kit+ (LSK) phenotype.
HSPC location and function require cellular quiescence and protection from
oxidative insult (92, 155, 199). Thus, antioxidant defense is vital to stem cell function.
This concept is demonstrated by the increase in stem cell function resulting from
treatment with the anti-oxidant and GSH precursor N-acetylcystiene (NAC) (85). This is
further demonstrated by the major cellular regulator of transcriptional anti-oxidant
signaling Nrf2. Nrf2-/- mice are characterized by an increase in HSPC differentiation and
a decrease in stem cell function, indicating that a loss of cellular antioxidant machinery is
detrimental to the maintenance of HSPC pools in vivo (219). These observations indicate
a potential role for glutathione metabolism and maintenance in the regulation of redox
balance and the resulting effect on differentiation and self-renewal, within normal and
malignant HSPC’s.
It is well recognized that regulation of glutathione metabolism is significantly
affected by the expression and activity of the ABC transporter ABCC1/MRP1 (multidrug resistance protein 1)(20, 107, 115, 116). MRP1 has wide tissue expression with the
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exception of the liver hepatocyte, functioning to efflux GSH, GSSG, and glutathione
adducted metabolites with a km in the low mM range for GSH and nM to µM range for
GS-X adducted metabolites (20, 54, 107, 115, 116, 144). While the role of MRP1 in
metabolism within peripheral and specialized tissues has been well documented, the
function of MRP1 and its effect on glutathione concentrations as well as the HSPC redox
state within primitive HSC’s is less understood. This is partially due to the inherently
limited availability of lineage primitive hematopoietic tissues, which display low
glutathione concentrations in vivo, and is compounded by the lack of sensitive
methodologies capable of discerning small dynamic changes in glutathione
concentrations within these specialized hematopoietic populations. However, the ability
to accurately quantitate cellular GSH pools within these rare tissues is needed because
aberrant GSH metabolism may lead to an alteration of the HSPC redox state. These
changes in HSPC redox balance are closely associated with genetic instability as well as
proliferation, differentiation, and mobility within the HSPC populations in which
hematopoietic disorders are thought to initiate and reside (90-92, 209). As such,
examining the GSH/GSSG based HSPC redox state may provide insight to the role of
MRP1 and the glutathione redox pair in the onset and progression of hematopoietic
neoplasms. Additionally, many cancer therapies, including radiation and
chemotherapeutics, such as the anthracyclines, are known to exert a portion of their
tumor killing effect through the production of ROS, which may be remediated by
adduction of GSH and efflux via MRP1, further altering the malignant cell redox state.
Together, these facets indicate that accurate measurement of GSH/GSSG will aid
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interpretation of MRP1 function in HSPC’s and how alterations in the cellular redox state
may affect hematopoietic disease onset, progression, and treatment.
Many current methodologies utilized for GSH and GSSG quantitation are based
on free thiol conjugation followed by the observation of a fluorescent product, enzymatic
reduction of glutathione disulfide pools, and the chemical derivation of parent glutathione
molecules allowing for chromatographic separation (22, 27, 151, 169, 175). These
methodologies require complicated chemical reactions, which may not reach completion,
and large amounts of sample tissue. Moreover, some methodologies may only accurately
measure total glutathione content and are not effective or ideal for accurately quantitating
GSH/GSSG in small cell populations in vivo, such as HSPC’s. However, emerging
methods that combine high performance liquid chromatography with single or tandem
mass spectrometry (LC-MS, LC-MS/MS) with and without post column sample
modification have quantitated GSH/GSSG in physiological fluids (32, 195). While these
methods demonstrate the potential power of LC-MS/MS analysis, they do so within an
effectively unlimited sample population. Here we describe the development and
validation of a simple tissue extraction combined with a robust and sensitive LC-MS/MS
method, demonstrating high throughput potential, for the direct and simultaneous
quantitation of oxidized and reduced forms of glutathione in small HSPC populations.
The application of this methodology is demonstrated in cell culture systems as well as
mouse bone marrow, including purified Lin-, c-kit+, Sca-1+ (LSK) populations.
Validation procedures performed were based on the recommended guidelines for LCMS/MS based analysis of small molecules in industry as set forth by the United States
Food and Drug Administration (2). As a method and model control, we examine cell
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populations demonstrating differential expression of MRP1 resulting in the
characterization of MRP1 functional effect on glutathione concentrations within primitive
HSPC populations in vivo. This control allows us to evaluate whether this LC-MS/MS
method can detect fine variations in glutathione concentrations with both in vitro and in
vivo systems. We have found that the over expression of MRP1 in MCF7 cells results in
decreased intracellular GSH/GSSG concentrations, while loss of Mrp1 expression in
Mrp1-/- HSPC’s resulted in the cellular accumulation of GSH and GSSG. These results
indicate that MRP1 expression may have a direct impact on the cellular redox state of the
HSPC population. Additional evaluation of the utility for this methodology is completed
through the quantitation of glutathione within cultured MDSL cells treated with
chemotherapeutics (doxorubicin and lenalidomide) that have been previously used for the
treatment of hematopoietic disorders such as acute myeloid leukemia (AML) or
myelodysplastic syndromes (MDS). Furthermore, we characterize glutathione
concentrations in normal human bone marrow as well as mononuclear cells isolated from
patients afflicted with acute myeloid leukemia. We found that acute myeloid leukemic
cells derived from human bone marrow demonstrate elevated levels of GSH, indicating a
potential mechanism by which leukemic stem cells balance elevated levels of oxidative
stress produced during proliferation.

Materials and Methods
HPLC Grade LC-MS/MS Materials
γ-L-Glutamyl-L-Cysteinyl-Glycine (GSH), γ-glutamyl-L-cyteinyl-glycine
disulfide (GSSG), ethylenediaminetetraacetic acid (EDTA), were purchased from Sigma-
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Aldrich (St. Louis, MO). Trichloroacetic acid was purchased from J. T. Baker (Center
Valley, PA). Chromatographic columns were purchased from Phenomenex (Torrance,
CA). HPLC grade solvents were purchased from Fisher Scientific (Pittsburgh, PA).
Formic acid and ammonium formate were purchased from Acros Organic (Pittsburgh,
PA).
Cell Culture
MDSL cells, a gift from Dr. Tohyama of Kawasaki Medical School, Okayama,
Japan, were cultured in complete MDSL media containing: IMDM media (ATCC;
Manassas, VA) supplemented with 20% FBS (GE Healthcare; Pittsburgh, PA), 1%
penicillin/streptomycin (Life Technologies; Grand Island, NY), and 15 ng/mL
recombinant human IL-3 (Peprotech; Rocky Hill, NJ). MDSL cells were cultured at both
5% and 21% O2, 5% CO2, at 37º C. MCF7 cells were cultured in DMEM media (Life
Technologies; Grand Island, NY) supplemented with 10% FBS and 1%
penicillin/streptomycin in 5% CO2 at 37ºC. MRP1 overexpressing MCF7 (MRP1-10, a
gift from Dr. Charles Morrow, National Institute of Health, Bethesda, Washington DC)
cells were cultured in DMEM media supplemented with 10% FBS and 1%
penicillin/streptomycin, 1.0 mg/mL G418, in 5% CO2 at 37ºC.
LC-MS/MS Methodology
Mass spectrometric analysis was performed on a TSQ Vantage triple quadrupole
mass spectrometer (Thermo Fisher Scientific, Waltham MA) coupled with an ion max
electrospray ionization source containing a HESI II probe operated in positive ion mode.
The GSH/GSSG MS/MS method development was accomplished by direct infusion of a
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GSH/GSSG standard (10 µg/mL) into the mass spectrometer at a flow rate of 5 µL/min.
Single reaction monitoring (SRM) was used to simultaneously analyze samples for GSH
and GSSG. The SRM’s for GSH (m/z 308.0 → m/z 84.0 + 161.9) and GSSG (m/z 613.1
→ m/z 231.1 + 354.9) were completed with collision energies and S-lens voltages
optimized for each individual transition. Other MS/MS method settings follow: Q1 and
Q3 resolution at 0.7 FWHM, scan width at 0.1 amu, scan rate at 0.1 seconds, and
collision gas pressure at 1.0 mTorr. Tune parameters were as follows: spray voltage at
2700 V, vaporizer temperature at 200° C, capillary temperature at 250° C, sheath and
auxiliary gas pressures at 35 and 10 arbitrary units, respectively. Liquid chromatography
was performed on a Shimadzu LC system containing a CBM-2A controller, a SIL-2A
auto sampler, and two LC-20 AD pumps (Canby, OR). Liquid chromatographic
separation of 10 µL sample injections were achieved on a Phenomenex Luna PFP(2)
analytical column (100 mm x 2.0 mm, 3 µm) and completed under isocratic conditions,
99% mobile phase A (H2O, 0.75mM ammonium formate, 0.01% formic acid), 1%
solvent B (methanol) at 250 µL/minute over an 11 minute total run time.
Calibration Standards and Quality Control’s
Stock solutions of GSH and GSSG were prepared at 1 mg/mL by dissolving 1.0
mg of pure powder stock in 1.0 mL of 2% TCA (1mM EDTA). One hundred µL aliquots
were then frozen at -80° C for no more than 7 days. Working stock solutions were created
by 1:10 serial dilutions of the 1.0 mg/mL stock solutions in 2% TCA (1mM EDTA). A
working GSH/GSSG stock solution was mixed at 10 µg/mL and subsequently used to
dilute working standard concentrations of 500.0, 250.0, 100.0, 50.0, 25.0, 10.0, 7.5, 5.0,
2.5, 1.0, 0.5 ng/mL for simultaneous GSH/GSSG standardization of the LC-MS/MS
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system. QC solutions of 5.0, 25.0, and 250.0 ng/mL (five injections at each
concentration) were also diluted from the 10 µg/mL working GSH/GSSG stock solution.
Standard curves and QC’s were prepared and run on each day of analysis. Data
acquisition and sample peak integration analysis was completed with Xcalibur software,
version 2.1 (Thermo Fisher). Standard, QC, and sample concentrations were calculated
with sample peak areas and linear equations (form y = mx + b) generated by external
standard curves for both GSH and GSSG.
Sample Extraction Methodology
Samples, prepared as described below, were pelleted in a 5 mL round bottom tube
by centrifugation in a swinging bucket rotor at 1300 rpm for five minutes. Supernatants
were carefully discarded by vacuum aspiration. Cells were then re-suspended in 75 µL of
extraction buffer (2% TCA; 1.0 mM EDTA) and incubated on ice for 15 minutes after
which samples were vortexed for 45 seconds and incubated on ice for a further 15
minutes. Sample pH was adjusted to 2.0 by mixing 50 µL of sample lysate with 50 µL of
Mobile phase A (HPLC grade H2O, 0.75 mM ammonium formate, 0.01% formic acid,
pH=3.0) and cellular debris was subsequently pelleted by centrifugation at 4,000 x g for
10 minutes. Supernatants were collected for LC-MS/MS analysis.
Method Validation
The linear range of detection for both GSH and GSSG was determined and
validated by the analysis of the standard curve and QC samples generated as described
above (n=3). A linear regression was used to determine the correlation coefficient (r2
value) after plotting the analyte peak area over the standard concentration. The inter-day
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𝜎

slope precision was expressed as the percent of the coefficient of variance (%𝐶𝑉 = (𝜇) ∗
100). Analyte stability at various temperatures was determined by repeat analysis at the
lowest QC concentration (n=5) and is presented as percent of the concentration originally
measured. Inter and intra-day precision was determined by repeat standard and QC
evaluation at three different concentrations within the determined linear range in
replicates of five (n=3). Again, precision is presented as %CV. The lower limit of
detection (LLOD) was determined by the lowest peak height that generated a signal to
noise ratio (S/N) greater than or equal to three (S/N ≥ 3) for both GSH and GSSG. The
lower limit of quantitation (LLOQ) for both analyte species was identified as the
minimum analyte concentration required to generate a signal to noise ratio greater than or
equal to five (S/N ≥ 5) as determined by standard addition analysis described below.
Because GSH and GSSG are produced endogenously, the cellular lysates
produced during sample extraction serve as the biological matrix. Thus, precision,
accuracy and percent recovery were evaluated by standard addition of known analyte
concentrations to whole cell lysates which were extracted at 30,000 cells per aliquot of
lysate. Mouse whole bone marrow was used for cross validation. Here, individual lysates
of 30,000 cells/sample were spiked with known amounts of standard GSH/GSSG
solution. To accomplish standard addition of MDSL cell lysates, 1.2 million MDSL cells
were lysed in 3.0 mL of extraction buffer (30,000 cells/ 75 µL of extraction buffer).
Then, 75 µL of lysate was added to 75 µL of blank extraction buffer or extraction buffer
containing four times the target analyte (GSH/GSSG) concentration and samples were
then incubated on ice for 30 minutes. After incubation, sample pH was adjusted to 2.0 by
mixing 50 µL of sample containing the blank lysate, +/- standard with 50 µL of mobile
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phase A. Samples were then spun down at 4,000 x g for 10 minutes and analyzed via LCMS/MS. Standard addition of mouse whole bone marrow was completed by preparing
individual aliquots of 30,000 cells to which 75 µL of either blank extraction buffer or
extraction buffer containing two times the target analyte concentration of GSH/GSSG
was added. Samples were then incubated on ice for 15 minutes after which the samples
were vortexed for 45 seconds each, followed by another 15 minute incubation period on
ice. Cellular debris was then pelleted by centrifugation at 4,000 x g, and the supernatants
were collected for LC-MS/MS analysis. Standard addition for both cell types was
completed at 4 concentrations; 0.0, 5.0, 50.0, 250.0 ng/mL for GSH and 0.0, 1.0, 5.0,
50.0 ng/mL for GSSG. Each standard addition concentration was evaluated in replicates
of n=5. Target analyte concentrations were evaluated by subtracting the basal
GSH/GSSG concentrations obtained by LC-MS/MS analysis of the blank samples from
the GSH/GSSG concentrations calculated from the standard addition samples. Precision
values at each standard addition concentration are expressed as % CV, described above.
Accuracy values are expressed as % bias, which is taken as the percent deviation of the
determined experimental concentration from the proposed theoretical concentration
(𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑉𝑎𝑙𝑢𝑒−𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑉𝑎𝑙𝑢𝑒

((

𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑉𝑎𝑙𝑢𝑒

determined as the [(

) ∗ 100). The percent recovery values were

(𝑇𝑜𝑡𝑎𝑙 𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛−𝑇ℎ𝑒 𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛)
𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝐵𝑙𝑎𝑛𝑘 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛

)∗

100].
GSH/GSSG Analysis of Cultured Cells
MRP1 protein expression in MCF7 WT and MRP1 overexpressing MCF7
(MRP1-10) cells was evaluated by flow cytometry analysis after incubation with a FITC
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conjugated antibody targeted to the first nucleotide binding domain (amino acids 617932) of human ABCC1/MRP1. MCF7 and MRP1-overexpressing MCF7 (MRP1-10)
cells were plated at 100,000 cells per well in 12 well plates and were subsequently
incubated in 5% CO2 at 37° C for 24 hours to allow for cellular attachment. Cells were
then mechanically harvested, counted by hemocytometer and 50,000 cells per sample
were aliquoted into 500 µL of PBS (pH=7.0 for LC-MS/MS analysis of GSH/GSSG as
described above. Similarly, prior to analysis, MDSL cells were plated at 200,000
cells/mL in a 24 well plate and were then incubated in 5% or 21% O2, 5% CO2, at 37° C
for 24 hours. Cells were then counted by hemocytometer and samples were diluted in 500
µL of PBS (pH=7.0) prior to LC-MS/MS analysis of GSH/GSSG. Total GSH and GSSG
concentrations (ng/mL) were converted to ng/sample by multiplying by total sample
volume, sample concentrations were then divided by the total number of cells extracted,
normalized to 20,000 cells per sample and reported as [GSH] and [GSSG] in ng/20,000
cells.
LSK Purification by FACS Analysis
Femurs and tibias were harvested from wild type (WT) and Mrp1 knock out (KO)
mice of the C57BL/6 background. Subsequently, bone marrow was aspirated with FACS
buffer (PBS, 2% HI-FBS pH=7.4) using a 2 mL syringe and a 27.5 gauge needle (BD
biosciences, San Jose, CA). Whole bone marrow was then pelleted by centrifugation at
1600 rpm for 3 minutes and the supernatant was discarded. Cells were then washed twice
with FACS buffer. Whole bone marrow was then re-suspended in red blood cell lysis
buffer (150 mM NH4Cl, 10mM NaHCO3, 1 mM EDTA), filtered through a 5 mL (12 x
75 mm) polystyrene round-bottom tube with a cell strainer cap (BD Falcon, San Diego,
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CA) and incubated on ice for 5 minutes. Cells were then spun down at 1600 rpm for 3
minutes and the supernatant was discarded. Cells were then washed twice with FACS
buffer and re-suspended in 100 µL of FACS buffer. After re-suspension cells were
incubated with 2 µL (1:50 ratio) of conjugated antibody corresponding to cell surface
markers used for sorting Lin- , Sca-1+, c-kit+ hematopoietic stem cells (LSKs) on ice for
60 minutes. The antibodies used for sorting LSK’s were as follows: Sca-1, Ly-6A/E-PECy7; c-kit, CD-117-PerCP-Cy5.5; Lineage, Cd45R-APC-Cy7, Cd3e-APC-Cy7, Ter199APC-Cy7, Cd19-APC-Cy7, and Cd11b-APC-Cy7 (all antibodies listed are raised in rat,
anti-mouse and were purchased at 0.2 mg/mL from BD Pharmigen, San Diego, CA).
Subsequent to incubation, cells were washed and then re-suspended in 500 µL of FACS
buffer for fluorescence assisted cell sorting of LSKs at the University of Kentucky flow
cytometry facility. There, Lin- , Sca-1+, c-kit+ HSC/MPP’s from both WT and Mrp1 KO
mice were sorted such that LSKs from two mice were pooled as n = 1 for GSH/GSSG
analysis. Thus, six mice of each genotype were sorted as three separate experimental
preparations (n=3). LSKs were then taken directly to the University of Kentucky
Proteomics Core for analysis of absolute GSH/GSSG concentrations via LC-MS/MS.
Cell Viability
MDSL cells were plated at a density of 200,000 cells/mL in complete MDSL cell
medium containing either vehicle or drug (10 µM Lenalidomide, Cayman Chemical, Ann
Arbor MI; or 25 nM Doxorubicin, Pfizer, New York, NY) in a 24 well plate and were
incubated for 48 hours. Cells were then transferred to 5 mL round bottom tubes and
washed twice with warm HBSS (pH=7.4)( Gibco-Thermo Fischer, Waltham, MA). Cells
were then re-suspended in MTT solution (0.5 mg/mL 3-(4, 5-dimethylthiazolyl-2)-2,556

diphenyltetrazolium bromide, Sigma Aldridge St. Louis, MO; in RPMI media with no
phenol red Gibco-Thermo Fischer, Waltham, MA), aliquoted into a 96 well plate, and
incubated at 37ºC for 4 hours. Equal volumes of lysis buffer (50/50, v/v,
isopropanol/DMSO) were added to each well followed by a 30 minute incubation at
37ºC. Samples were then evaluated for absorbance at 560 and 690 nm using a Molecular
Devices SpectraMax Plus 384 plate reader with SoftMax Pro software.
Therapeutic Drug Treatments
MDSL cells were plated at a density of 200,000 cells/mL in complete MDSL cell
medium containing either vehicle or drug (10 µM lenalidomide, Cayman Chemical, Ann
Arbor MI; or 25 nM doxorubicin, Pfizer, New York, NY) in a 24 well plate and were
incubated for 6 hours. Samples were then transferred to 5 mL round bottom centrifuge
tubes, extracted, and GSH/GSSG concentrations were analyzed via LC-MS/MS as
previously described.
Patient Sample Collection and Analysis
Peripheral blood and bone marrow samples were obtained by Dr. Diana Howard,
from the Markey Cancer Center after individuals gave informed consent for tissue
donation. White blood cells were isolated by Ficoll gradient centrifugation as follows;
patient tissue (21 mL of blood or bone marrow) was diluted to 50 mL with phosphate
buffered saline (Sigma Aldridge). Samples were then layered over 13 mL of Histopaque
(Sigma Aldridge) and centrifuged at 1400 rpm for 45 minutes. The white blood cell layer
was then carefully removed, diluted in freezing media (IMDM, 10% FBS, 1%
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penicillin/streptomycin, 10% DMSO) and stored in liquid nitrogen (-180° C) until the
time of LC-MS/MS analysis, as described above.
Statistics
Statistical analysis for method validation was completed as described by the
USFDA guidelines for LC-MS/MS bioanalytical method validation. Lower limits of
detection were taken as the analyte derived signal that produced a peak with a signal to
noise ratio 3 times greater than the background matrix. The lower limit of quantitation is
defined as the analyte concentration required to generate a signal to noise ratio greater
than or equal to 5 times the signal to noise ratio of the background matrix. For specific
guidelines see the method validation section above. Inter and Intra-day precision are
presented as a percent of the coefficient of variance (%CV). Calculations are based on
replicate measurements (n=5) at three different QC concentrations, three separate times
(n=3). Accuracy is presented as a percent bias of experimentally observed concentrations
compared to the theoretical concentrations measured in replicate analysis (n=5) for 3
different concentrations, 3 separate times (n=3). Standard curves are presented with a
95% confidence interval based on 3 separate measurements (n=3). GSH and GSSG are
statistically compared separately between control and genetic or treatment groups. Pvalues between control and treatment groups are calculated via t-test (n=3). Unless
otherwise stated, error is presented as the standard error of the mean derived from at least
three experimental repeats containing a minimum of triplicate measurements.
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Results
LC-MS/MS Method Development and Validation
Past liquid chromatographic separation of glutathione has been accomplished with
common reverse phase C18 columns. However, we have found that GSH retention on
these analytical columns is minimal. Squellerio et al., (195) described utilization of the
Luna PFP-2 reverse phase column (Phenomenex) for the efficient retention of both
glutathione species in the LC-MS/MS analysis of GSH and GSSG from human whole
blood samples. In agreement with their findings, we found the Luna PFP-2 column to be
the optimal tool for chromatographic retention and separation of the oxidized and reduced
glutathione species. While previous mass spectrometric based methodologies for the
analysis of GSH/GSSG in physiological fluids have been characterized, these methods
are applied to the analysis of samples for which there effectively is a nearly unlimited
supply (32, 195). To our knowledge, none have examined the limits of sensitivity and
potential for analysis of fine changes in GSH/GSSG concentrations within rare and
limited tissue populations, such as hematopoietic stem cells in vivo.
To determine the quantitative limit for tissue sample analysis of GSH/GSSG
concentrations in vitro and demonstrate the effectiveness and sensitivity of these
analytical parameters in vivo, we developed a modified LC-MS/MS method for direct and
simultaneous GSH/GSSG quantitation. The product ion spectra obtained were evaluated
by the comparison to product ion spectra acquired from the direct infusion of pure
GSH/GSSG standard (Figure 2.1A). The chromatographic resolution of GSH and GSSG
was confirmed by the collection and evaluation of full product ion spectra resulting from
the analysis of GSH and GSSG from a biological sample (Figure 2.1B). Upon completion
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of the LC-MS/MS SRM method development, the average retention times for GSH and
GSSG elution from the Luna-PFP2 reverse phase column, calculated from QC analysis
were 2.69 +/- 0.02 and 4.37 +/- 0.03 minutes respectively (mean +/- SD, n=15). A
typical extracted ion chromatogram obtained from LC-MS/MS analysis of a 25 ng/mL
standard is shown in Figure 2.2. Figure 2.3 demonstrates the typical results obtained from
GSH/GSSG standard curve analysis. Although separate external GSH and GSSG
standard curves are generated, standard data acquisition occurred simultaneously.
The method validation summary (Table 2.1) includes all parameters for LCMS/MS method validation as recommended by the USFDA(2). The lower limit of
detection for both GSH and GSSG was 0.5 ng/mL as demonstrated by chromatographic
peaks that have a signal to noise ratio greater than 3. Precision, lower limits of
quantitation (LLOQ) as determined by accuracy measurements at various QC
concentrations, and analyte recovery were all determined by standard addition analysis.
The lower limits of analyte quantitation were 5.0 ng/mL for GSH and 1.0 ng/mL for
GSSG.
The USFDA recommends that accuracy values, which are defined as the
closeness of a concentration value obtained by the analytical method to the actual
concentration value, and precision values, defined as the closeness of individual measures
of an analyte when the procedure is applied to multiple aliquots of a single homogenous
solution of biological matrix, must be evaluated at three different concentrations within
the analyte’s linear range and must have five repeat evaluations at each concentration.
These analyte evaluations must have mean coefficient of variance values within 15% at
medium and high concentrations within the analyte’s linear range, and 20% at the LLOQ
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(2). Table 2.1 summarizes the results of this LC-MS/MS method validation. Analyte
stability was evaluated at the lowest QC concentration (5 ng/mL) for storage at 3
different temperatures. Our results agree with those previously reported, demonstrating
good GSH/GSSG stability within 15%, at +4° C and -80° C. However, GSH stability, at
the LLOQ, was slightly diminished (-23%) at room temperature after a period of 24
hours. Slope and inter/intra-day precision values had coefficient of variance values less
than 10% (Table 2.1). A full method validation was completed in MDSL cell lysates in
which the accuracy values were all within 20% at the LLOQ (GSH, 17.4%; GSSG, 1.6%) and medium to high concentrations demonstrated CV values of less than 5%
(Table 2.1). Precision %CV values were less than 15% at all concentrations for both GSH
and GSSG. Analyte recovery values, evaluated by standard addition, were all within 10%
of full analyte recovery for both GSH and GSSG. Finally, a method cross validation by
evaluation of accuracy and precision via standard addition was completed in the mouse
whole bone marrow biological matrix. Accuracy and precision coefficient of variance
values were determined to be within 15% at all concentrations for both GSH and GSSG.
Biological Method Evaluation
To test the potential for this method to evaluate varying glutathione levels in
biological systems, we utilized a system with altered expression of Multidrug Resistanceassociated Protein 1 (ABCC1/MRP1). We first measured GSH/GSSG levels in MCF7
wild type cells, known to not express MRP1, and compared these results to the
GSH/GSSG measurement within MCF7 cells overexpressing MRP1 (MRP1-10 cells).
Differential MRP1 expression between the two MCF7 cell lines was confirmed by flow
cytometric analysis of FITC conjugated antibody directed to the first nucleotide binding
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domain of human MRP1 (Figure 2.4). Figure 2.5A shows that overexpression of MRP1
resulted in a significant decrease in cellular GSH and GSSG concentrations, -0.65 ng/20k
cells for GSH, and -0.13 ng/20k cells for GSSG (p=0.001). Figure 2.5B shows that MRP1
overexpression in MCF7 cells (MRP1-10 cells) results in a significant increase in the
GSH/GSSG ratio, +5.3 (p=0.01).
This method was then used to evaluate GSH/GSSG concentrations in the absence
of MRP1 in vivo. Both WT and Mrp1-/- C57BL/6 mice were obtained and their
hematopoietic stem cells (Lin-, sca-1+, c-kit+; LSK’s) were isolated via fluorescence
assisted cell sorting (Figure 2.6). The typical yield for this isolation was approximately
20,000 cells from a single animal. The results demonstrated that the LSK cells from
Mrp1-/- mice had a significant increase in cellular GSH concentrations (+4.6 ng/20k cells,
p=0.01). Although differences in the GSSG concentration were observed in LSK cells
isolated from Mrp1-/- and WT mice, these changes were not judged to be statistically
significant (Figure 2.7). These results demonstrate the robustness and sensitivity of our
LC-MS/MS methodology and its ability to detect fine differences in GSH/GSSG
concentrations within very limited tissue populations.
Both the over expression and knock out of Mrp1 expression within various cell
types resulted in an increase of the GSH/GSSG ratio. This indicates that the evaluation of
the individual cellular concentrations of GSH and GSSG and not only their concentration
but also their ratio is useful for an accurate interpretation of the GSH/GSSG based
cellular redox state.
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To further validate the utility of the methodology, MDSL cells were evaluated for
GSH and GSSG concentrations after treatment in vitro with two clinically relevant
chemotherapeutic agents, doxorubicin (Adriamycin) and lenalidomide (Revlimid).
Traditionally, high risk MDS patients presenting with blast crisis have been treated with
high dose cytarabine plus an additional course of an anthracycline such as doxorubicin.
Because doxorubicin is a known ROS inducer, due to its metabolic formation of an
intermediate semi-quinone structure, we compare the treatment effect and generation of
ROS via doxorubicin to that of lenalidomide. Lenalidomide is known to act as an antiinflammatory agent as well as a stimulant of lymphocytes and erythropoiesis (44, 130,
145, 179). However, there is evidence that suggests lenalidomide can, itself, induce
oxidative stress. This is observed in the use of lenalidomide for the treatment of a
multiple myeloma model in which the combination of lenalidomide and the spin trap,
ROS scavenger, phenyl-N-t-butylnitrone (PBN) effectively modulates the transcriptional
activation of AP-1 family transcription factors (43). Recently, lenalidomide has been
proven to be effective in the treatment of MDS mouse models and has a significant
cytotoxic effect in vitro, at 10 μM (173). Doxorubicin (25 nM) and Lenalidomide (10
μM) treatment of MDSL cells results in 21% (p=0.04) and 18% (p=0.02) decreases in
MDSL cell viability, respectively (Figure 2.8). Similar treatment effects are also
demonstrated on cellular GSH and GSSG concentrations in vitro. A 6 hour treatment of
MDSL cells with Doxorubicin resulted in a 19% depletion of GSH (-5.72 ng/20k cells,
p=0.03) and a 15% (-0.019 ng/20k cells, p=0.03) depletion of GSSG compared to vehicle
control (Figure 2.9). Similarly, 6 hour in vitro treatment of MDSL cells with
Lenalidomide resulted in a 10% (-2.09 ng/20k cells, p=0.01) depletion of GSH and a 15%
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(-0.013 ng/20k cells, p=0.02) depletion of GSSG, compared to vehicle controls (Figure
2.9). Because the decreases in GSH and GSSG upon treatment were very fine, there was
no significant difference in the GSH/GSSG ratio’s between treatment and control groups.
This again points to the importance of individual species concentration determination
rather than the examination of the ratio between the reduced and oxidized forms of
glutathione alone. Furthermore, the elucidation of such minor, yet significant, changes in
analyte concentration demonstrates the sensitivity and robust nature of this methodology.
Patient Sample Evaluation
Because cellular GSH/GSSG concentrations could play a significant role in
disease onset and progression, changes in cellular GSH/GSSG concentrations and the
cellular redox state may potentially serve as a biological marker for disease onset or
severity. As such, we set out to evaluate GSH/GSSG concentrations in Ficoll purified
white blood cell populations from patient samples donated by healthy individuals or those
who had a confirmed case of a hematopoietic malignancy. We measured GSH/GSSG
concentrations in 5 samples collected from healthy bone marrow (NBM), and 6 samples
from patients diagnosed with acute myeloid leukemia (AML). Figure 2.10 shows a
significantly higher GSH levels in AML compared to the NBM samples (+ 18.57 ng/mL),
resulting in an increased GSH/GSSG ratio (+2.87). This elevated GSH/GSSG redox state
may compensate for the elevated oxidative stress levels that malignant cells utilize for
proliferation and disease progression.
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Discussion
Recently, several mass spectrometric based methodologies have directly
evaluated oxidized and reduced glutathione extracted from physiological fluids. These
methods measure GSH/GSSG concentrations without the need for the enzymatic
reduction or chemical derivation of glutathione or glutathione disulfide prior to endpoint
detection (22, 32, 151, 195). While effective, previous methods have been applied only to
large sample pools in which the limits of sample volume and method sensitivity are not
an issue. Following the USFDA Guidance for Industry on Bioanalytical LC-MS/MS
Method Validation, we have developed and described the validation of a sensitive and
robust LC-MS/MS method for the simultaneous and direct quantitation of the oxidized
and reduced forms of glutathione. We apply this methodology to the quantitation of GSH
and GSSG at the cellular level, and we use this method to determine the lower limit of
tissue volume required for accurate cellular GSH/GSSG quantitation. We have
demonstrated the quantitation of cellular GSH/GSSG within the murine stem cell
populations and the potential for GSH/GSSG analysis within HSCs derived from an
individual animal. Our analyses enable the determination of the physiologically relevant,
functional effect of MRP1 expression on the glutathione based redox state within
primitive HSC populations. Here, loss of MRP1 expression results in an increase in
cellular glutathione concentrations, creating a more reducing intracellular environment.
This result indicates that MRP1 may play an important role in regulating redox balance
within HSC’s and thus influencing the ability or proclivity for HSCs to self-renew or
differentiate into downstream functional populations. Additionally, the ability to detect
clinically relevant treatment induced variations in glutathione concentrations within
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hematopoietic tissues, as demonstrated by the treatment of MDSL cells with doxorubicin
and lenalidomide, show that this methodology may be capable of providing valuable
insight to treatment toxicity as well as efficacy as it pertains to the modulation of the
cellular redox state in vivo.
Because of the critical role of glutathione in cellular redox balance and signaling,
we believe that the tissue extraction and LC-MS/MS method described here will become
an important tool for examining how the cellular redox state may affect or be affected by
the development and treatment of hematopoietic neoplasms. Based on the data obtained
from human samples, we speculate that elevated redox stress within malignant
hematopoietic cells may be compensated with elevated levels of GSH and that the altered
redox state may support disease onset as well as drive disease progression(100). The
results suggest that there is a potential for the future use of cellular GSH/GSSG
concentrations as a bio-marker for hematopoietic cancer; however, a much larger patient
cohort must be evaluated.
GSH concentrations in the nucleus account for 10-15% of total cellular GSH, and
1-2% of this total cellular GSH pool residing in the nucleus may be resistant to depletion
by chemical agents such as L-buthionine-[S,R]-sulfoximine (BSO) (23, 52, 53, 97, 206).
Thus, characterization of nuclear GSH concentration and function can indicate GSH
utility in nuclear protection from oxidant insult, resulting in the faithful conservation of
DNA replication and improved DNA repair capabilities. Similarly, mitochondrial GSH
may account for up to 30% of cellular GSH (123, 125, 133, 192). This mitochondrial
pool of GSH protects other sulfhydryl containing proteins and may partially regulate the
function of ATPases, transporters, and dehydrogenases by buffering the cellular redox
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status in the face of oxidative challenge (192). Due to its sensitivity, our method may be
utilized for the evaluation of GSH/GSSG concentrations within separate subcellular
fractions, such as nuclear extracts and purified mitochondrial preparations. Future efforts
to characterize subcellular GSH pools within rare tissue populations may be
accomplished by adopting this LC-MS/MS methodology into an ultra-high pressure
liquid chromatographic (UHPLC) system. The features of UHPLC-MS/MS analysis
result in tighter peak widths and greater peak heights resulting in improved overall
analyte sensitivity and higher throughput potential. Utilization and further development
of the methods we describe here can have an important impact on redox biology research
as it pertains to the development of hematopoietic malignancies in limited and rare tissue
populations as well as the impact of redox balance on subcellular function.
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Figure 2.1GSH/GSSG MS/MS spectra
A.) Both GSH (top) and GSSG (bottom) were infused in line with a 50% solvent A (H2O, 0.1% formic acid), 50% solvent B (acetonitrile,
0.1% formic acid) LC flow (200 µ/in) at a rate of 5 µL/min and at concentrations of 10µg/mL. The resulting product ion spectra were obtained
from GSH and GSSG parent ions. B.) The chromatograms and spectra above resulted from the injection of a cellular extract isolated from
mouse LSK cells. The spectra below each chromatogram display the product ion spectrum for the highlighted chromatographic peak above.
Comparison of these spectra with the infusion spectra (A) shown above confirms the presence of GSH and GSSG.

Figure 2.2 Chromatographic separation of GSH and GSSG
The chromatograph above demonstrates the simultaneous separation of reduced (GSH,
middle) and oxidized (GSSG, bottom) forms of glutathione. This injection sample
consisted of 10 µl of a 25 ng/mL QC sample (0.25 ng on column) routinely run during
instrument standardization.
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Figure 2.3 External linear range of GSH and GSSG standards
The linear plots above are examples of typical standard curves for both GSH and GSSG.
Although separate curves are generated, GSH and GSSG standardization of the LC-MS/MS
system takes place simultaneously. 1 mg/mL standards for GSH and GSSG are prepared in 1%
TCA (1.0 mM EDTA, 50% solvent A). These standards are then mixed at 10 µg/mL each and
are subsequently diluted down in a stepwise fashion with 1%TCA (1.0 mM EDTA, 50%
solvent A) to create the working solutions of standard and QC concentrations displayed in the
linear range above. Fresh standards and QC’s are prepared the day sample analysis takes
place. Data are presented with a 95% confidence interval, n=3.
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Table 2.1 GSH/GSSG LC-MS/MS method validation summary
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Table 2.1 GSH/GSSG LC-MS/MS method validation summary
The table above summarizes the results of the LC-MS/MS method validation for the
simultaneous analysis of reduced and oxidized forms of glutathione. The Lower Limit of
Detection and Quantitation were taken as the concentrations which exhibit a signal greater
than or equal to that of three (LLOD) and five (LLOQ) times the intensity of a blank matrix
injection respectively. All standards and QC’s had an injection volume of 10 uL and were
analyzed using the LC-MS/MS method previously summarized. Inter-day standard and slope
analysis was completed over 3 days with a linear range of 0-500 ng/mL. QC’s levels
evaluated were at 5, 25, and 250 ng/mL over 3 days for inter-day precision analysis. Intra-day
precision analysis was completed with an n=5 for each concentration on the same day.
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Figure 2.4 MRP1 expression in MCF7 cells
MRP1 expression evaluated with a FITC conjugated antibody in MCF7 WT (red), and
MCF7 cells overexpressing MRP1 (MRP1-10, blue and orange).
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Figure 2.5 MRP1 expression effects on cellular GSH and GSSG concentrations
A) Mean GSH/GSSG concentrations were evaluated in MCF7 WT and MCF7 cells
overexpressing MRP1 (MRP1-10). Significant differences in GSH concentration between
MCF7 (1.46 ng/20k cells) and MRP1-10 cells (0.81 ng/20k cells) were determined (p=0.001).
Additionally, significant differences in GSSG concentration between MCF7 (0.19 ng/20k
cells) and MRP1-10 cells (0.06 ng/20k cells) were determined (p=0.001). B) Average
GSH/GSSG ratios between MCF7 WT (7.5) and MRP1-10 (12.8) cells were found to be
significantly different (p=0.01). GSH and GSSG were statistically compared separately
between the two genetic groups via t-test (n=3), *p< 0.01. Error is expressed as standard error
of the mean.
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Figure 2.6 FACS isolation of LSK populations
-

+

+

Fluorescence Assisted Cell Sorting (FACS) purification of Lin , Sca-1 , c-kit (LSK)
hematopoietic stem cells (HSC’s). Bone marrow from C57BL6 wild type (WT, Bottom) and
Mrp1 knock out (KO, Top) mice used for GSH/GSSG analysis. This analysis routinely resulted
in the purification of approximately 20,000 cells per mouse.
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Figure 2.7 Cellular glutathione concentrations in LSK populations
The concentrations of GSH, GSSG and their cellular ratio determined in WT and Mrp1 KO
mouse LSK cells purified as described earlier. The graph depicts the differences in analyte
concentrations between genotypes. A significant difference in mean GSH concentration is
demonstrated between the Mrp1 KO (5.64 ng/20k cells) and WT (1.04 ng/20k cells) animals
(p=0.01). A difference in the GSSG concentration between genotypes was found (KO, 1.07
ng/20k cells vs WT, 0.17 ng/20k cells) but this difference was not statistically significant.
Similarly, no significant statistical difference in GSH/GSSG ratios was determined (KO, 8.56 vs
WT, 6.16). GSH and GSSG were statistically compared separately between the two genetic
groups via t-test (n=3), *p< 0.05. Error is expressed as standard deviation.
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Figure 2.8 Chemotherapeutic toxicity in MDSL cells
MDSL cell viability was evaluated via MTT assay after 48 hour treatment with 25 nM
doxorubicin and 10 µM lenalidomide in vitro. Both treatments resulted in a significant
decrease of cell survival, 21% for doxorubicin (p=0.04) and 18% for lenalidomide (p=0.02) .
Results are expressed as percent cell survival normalized to their individual vehicle control
and as such are statistically evaluated as separate groups using the t-test (n=3), *p<0.05. Error
is expressed as standard error of the mean.
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Figure 2.9 Chemotherapeutic depletion of GSH and GSSG
MDSL cell GSH (A) and GSSG (B) concentrations were analyzed after 6 hour drug
treatment in vitro. Both Doxorubicin (25 nM) and Lenalidomide (10 μM) caused
significant depletion of GSH and GSSG (Dox GSH -5.72 ng/ 20k cells, p=0.03; Dox
GSSG -0.019 ng/20k cells, p=0.03; Len GSH -2.09 ng/20k cells, p=0.02; Len GSSG 0.013 ng/20k cells p=0.01). Each analyte species and treatment group was statistically
evaluated separately in comparison to their own unique vehicle controls using a t-test
(n=3), *p<0.05. Error is presented as standard error of the mean.
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Figure 2.10 Glutathione concentrations in patient samples
Mean GSH, GSSG concentrations and their cellular concentration ratio
analyzed within lymphocytes purified from the peripheral blood and bone
marrow of AML and normal healthy donors. LC-MS/MS analysis revealed a
significant increase in GSH concentrations within the AML (28.15 ng/mL,
n=6) vs NBM (9.58 ng/mL, n=5) sample populations (p=0.03), resulting in a
significant increase in the GSH/GSSG ratio, 3.94 in AML vs 1.16 in NBM
patients (n=5, p=0.04). No statistically significant difference was determined
in GSSG concentrations between patient groups (AML, 8.77 ng/mL vs
NBM, 7.73 ng/mL). Analyte groups were evaluated separately via t-test,
error is expressed as standard deviation.
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Chapter Three: Mechanistic Insights to a Redox Based Therapy for Myelodysplastic
Syndromes
Introduction
The myelodysplastic syndromes (MDS) are a heterogeneous group of
myeloproliferative disorders (MPD) that clinically present with multiple cytopenia’s
within the myeloid lineage, a diverse set of cytogenetic abnormalities, and elevated blast
cell counts within the periphery. There are several accepted methods for evaluating MDS
and patient prognosis that include the World Health Organization (WHO), French
American British (FAB), and International Prognostic Scoring System (IPSS) systems.
Generally, these methods are used to evaluate the combinations of patient pathologies
resulting in a prognostic score acting as an outcome predictor that aids in treatment plan
identification. Patients who demonstrate few cytopenia’s with only one cytogenetic
abnormality such as a deletion on chromosome 11, and low blast cell counts of less than
2% in the periphery are given a very good risk score and a good prognostic outlook.
These individuals may receive treatment that supports normal hematopoiesis such as
erythropoietin, stem cell factors, and granulocyte-macrophage stimulating factors, to
combat potential risk of progressing cytopenia’s and development of anemia. Higher risk
patients who display several chromosomal rearrangements and deletions as well as 5% to
greater than 10% blast cell content within the periphery may receive first line therapies
that include hypomethylating agents and lenalidomide (138-141). However, nearly 50%
of patients show poor response to therapy. Those patients who are of high risk may
receive treatment for acute/chronic myeloid leukemias in blast crisis that includes
cytarabine alone or in combination with an anthracycline, with the only total curative
measure being an allogenic bone marrow transplant. However, advanced age and severity
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of disease within most patients limits treatment aggression and contributes to poor overall
survival rates.
While MDS is a relatively rare bone marrow disorder, approximately 30% of
patients progress to onset of acute myeloid leukemia (AML). This offers potential insight
into latent hematopoietic failure that is a prelude to prolific expansion of myeloid
compartments after complete malignant transformation. Thus, MDS offers a platform for
the identification of not only factors that contribute to bone marrow failure and cancer
development, but also elucidation of specific molecular targets that may be developed for
therapeutic applications. Because MDS is a relatively rare disorder, reliable model
systems that incorporate several facets of developed MDS are particularly useful (174).
Wunderlich and colleagues have described the development of NOD/SCID based
mice that contains a complete IL-2 receptor γ-chain (IL-2R) knock out (NSG mice) and a
separate model that express human forms of interleukin 3 (IL-3), stem cell factor (SCF),
and granulocyte-macrophage colony stimulating factor (GM-CSF) (NSS mice) (237). The
cross between the two mice results in the generation of the NSGS mouse model, a
NOD/SCID mouse that contains an IL-2R knock out and also expresses hIL-3, hSCF, and
hGM-CSF that allows for enhanced engraftment capabilities through decreased immunorejection and cytokine supported clonal expansion. The development of the NSG and
NSGS mice have allowed for improved engraftment of pre-leukemic and fully
transformed malignant cells in vivo (237). More recently, Rhyasen, Starczynowski and
colleagues have utilized these mouse models for the successful engraftment of a patient
derived clonal MDS cell line (MDSL) for the study of lenalidomide and an interleukin
receptor associated kinase-1 (IRAK1) inhibitor efficacy (173, 174). The engraftment of
81

the MDSL cell line has proven to be a useful tool for modeling the latent MDS
transforming to an aggressive form of MDS with significant engraftments within the bone
marrow and spleen. This MDSL cell line derived from a patient in the non-leukemic
phase of a myelodysplastic syndrome has been previously characterized as a
stem/progenitor phenotype that expresses both CD34 and CD38 and has low potential for
differentiation making it ideal for the identification of druggable mechanistic targets
within a non-leukemic clone (130, 174).
As previously discussed, increased resistance to hypomethylating agents,
malignant transformation, and aggressive treatment options for patients of advanced
disease and age, all point to the need for more effective therapeutics in areas that include
not only the suppression of malignant expansion, but the restoration of normal
hematopoiesis within the bone marrow niche. Recently, JunB has been identified as a key
factor for controlling the expansion of myeloid progenitor compartments. JunB deficient
models demonstrate the development of a myeloproliferative disorder in vivo, which
closely resembles myelodysplastic syndromes (156-158, 177). Within 3-6 months, JunB
deficient mice demonstrate granulocytic progenitor and blast cell expansion within bone
marrow and spleen followed by penetration of peripheral organs that is transferrable to 1°
and 2° naive recipients (156-158, 177). This MPD progresses through a defect in LTHSC differentiation through loss of response to Notch, TGF-β, and Wnt signaling as well
as INK4a cell cycle regulators (156-158, 177). These seminal studies present JunB as a
potentially druggable target that may aid in the return of normal hematopoiesis within
myeloproliferative disorders. Because the AP-1 family of transcription factors are known
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to be regulated by alterations to their intermolecular redox status, we examine the
potential application of redox therapeutic approach to JunB activation.
We have recently discovered that the manganese porphyrin MnTnBuOE-2-PyP5+
(MnP) successfully aids normal hematopoiesis through short-term and multipotent
progenitor cell populations, made evident most notably through naive tertiary transplant
recipients receiving donor derived bone marrow treated with MnP in vivo (256). This
occurs through a redox mechanism that relies on the MnP metabolism of superoxide and
the production of hydrogen peroxide. Because MnP has been extensively characterized
and has demonstrated anti-tumor activity in a variety of malignant cancer models (15, 93,
210, 211), we evaluate MnP in vitro as a potential MDS therapy and utilize the MDSL
cell line to identify redox modification of the AP-1 family transcription factor JunB, and
present JunB as a viable drug target for MnP treatment of MDS.
Materials and Methods
Cell Culture and Treatments
MDSL cells were cultured in complete MDSL media: IMDM medium containing
1x penicillin/streptomycin and 20% FBS. MDSL cell culture media was supplemented
with 15 ng/mL human IL-3 (Peprotech; Rocky Hill, NJ). All cultures were kept in a
humid environment at 37° C supplemented with 5% CO2. MnP was synthesized and
characterized by Dr. Ines Batinic-Haberle and her colleagues at Duke University School
of Medicine; Durham, NC. Where indicated, MnP treatment alone was accomplished by
supplementing culture medium with drug at indicated concentrations and durations.
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Where indicated, cells were treated with PEG-Catalase (Sigma Aldrich, St. Louis, MO) at
a concentration of approximately 80 Units/cell for 12-16 hours overnight.
Cell Viability
Cell viability was determined by two different assays. First, viability was
determined using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide) assay. Cells were plated at a density of 100,000-200,000 cells/mL and were
incubated with indicated drug treatments for 48 hours. At the time of analysis, samples
were collected and transferred to 5 mL round bottom polystyrene tubes (Corning;
Harrodsburg, KY), pelleted via centrifugation at 1300 rpm for 5 minutes and
subsequently washed twice with sterile PBS. Samples were then resuspended in DMEM
media containing no phenol-red supplemented with 0.5 mg/mL MTT reagent. Cells were
re-plated in a 96 well plate at 30,000 cells/well and incubated at 37° C (5% CO2) for 3.5
hours. Cells were then lysed with 1:1 (v/v) DMSO and isopropanol and incubated for 25
minutes in the dark. Absorbance was then measured at 560 and 690 nm. Additionally,
cell viability was determined by flow cytometry. Normal human bone marrow cells
purchased from All Cells were rapidly thawed and washed 3 times with IMDM media
after which cell viability was accounted for via trypan blue staining. Cells were then
plated out and treated with MnP at indicated concentrations over night for 18 hours. Cells
were then collected and washed twice with PBS. Samples were then incubated with
fluorochrome conjugated antibodies to CD34 and CD38 in FACS buffer (PBS, 2% FBS)
for 1 hour in the dark. Samples were washed in FACS buffer and resuspended in 500 μL
FACS buffer containing 5 μL of 5 mg/mL propidium iodide. Samples were then
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evaluated for viability by exclusion of propidium iodide via flow cytometry with an LSR
II (BD Biosciences; Franklin Lakes, NJ).
Glutathione Quantitation, Cellular Volume, Intracellular pH and Reduction
Potential Calculation
We have previously summarized the development, validation, and implementation
of simultaneous GSH and GSSG quantitation via LC-MS/MS. Briefly, treated samples
and controls were transferred, at 30,000 cells per sample, to 5 mL round bottom
polystyrene centrifuge tubes and were subsequently pelleted at 1300 rpm for 5 minutes.
Supernatants were vacuum aspirated and cells were subsequently lysed in an ice cold 2%
TCA solution containing 1 mM EDTA, vortexed for 30 seconds and incubated on ice for
15 min. Samples were then vortexed a second time and were further incubated on ice for
15 minutes. Cellular debris was then pelleted at 4,000 x g for 10 minutes and sample pH
was adjusted to 2.0 prior to LC-MS/MS analysis. Samples concentrations were calculated
based on external standard curve analysis with the linear form 𝑦 = 𝑚𝑥 + 𝑏. Sample
concentrations in ng/mL were converted to moles of analyte using the molar mass for
glutathione and glutathione disulfide. This conversion was then used to calculate the
molar analyte concentrations per cell after cellular volume determination.
Cellular diameter was determined via the Coulter principal and electrical
impedance. This was accomplished with a Scepter cell counter (Millipore Sigma;
Burlington, MA). Samples were collected, washed twice with PBS and analyzed with a
40 μm sensor. Average cellular diameters were then used in the equation for the volume
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of sphere, 𝑉 = 3 𝜋𝑟 3 , to calculate cellular volume. This value was used to divide analyte
concentrations (moles) resulting in cellular molar analyte concentrations.
Intracellular pH was evaluated with BCECF (2’,7’-bis-(2-carboxyethyl)-5-(and6)-carboxyfluorescein) (Invitrogen) fluorescence. High potassium Ringer’s solutions
(142.3 mM KCl, 1.0 mM MGCl2, 1.5 mM CaCl2, 10 mM NaCl, 20 mM HEPES) were
prepared for standard curve analysis at various pH values (6.21, 6.85, 7.17, 7.77). Cell
samples evaluated as standards were washed and resuspended in Ringer’s solution of the
designated pH and were subsequently treated with nigericin (3 μM) for H+/K+
equilibration for 30 minutes at room temperature. 1.0 x 106 cells were treated with either
vehicle or MnP. Samples were then washed and both standards and samples were treated
with 3 μg/mL BCECF in PBS for 1 hour at room temperature. Samples and standards
were then washed and fluorescence was measure at excitation 440/490, emission 530.
Molar concentrations were then used to calculate the glutathione-based half-cell
reduction potential at 25°C, pH 7.0 as summarized by Schaffer and Buettner (178).

𝐸ℎ𝑐 = −240 − (

59.1
2

[𝐺𝑆𝐻]2

) log ( [𝐺𝑆𝑆𝐺] )

Measurement of Intracellular Hydrogen Peroxide
Measurement of intracellular hydrogen peroxide has been previously described by
Wagner and Buettner (227). Briefly, samples and controls were plated in 6 well plates,
treated with 20 mM 3-aminotriazol (Sigma Aldrich; St. Louis, MO) and subsequently
harvested at 0, 5, 15, 30, 45, and 60 minutes. Cells were washed and subsequently lysed
in 250 uL of 50 mM phosphate buffer pH 7.0 via sonication; 500 uL of 30 mM H2O2 in
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phosphate buffer was added to 1.0 mL of sample and the loss of absorbance at 240 nm
was observed at 15 second intervals for 2 minutes. The natural log of the result from each
time point is plotted against time (in seconds) and the slope is taken as the first order rate
constant for the inactivation of catalase in the presence of 3-AT (kinactivation). Steady state
hydrogen peroxide concentrations are then calculated from the equation:
[H2O2]ss=kinactivation/k1
Where k1= 1.7 x 107 M-1s-1, which is the rate constant for compound I formation in the
presence of hydrogen peroxide.
Transcription Factor ELISA Array
Transcription ELISA kit was obtained from Signosis (Santa Clara, CA) and all
procedures were conducted according to the instructions provide with the assay kit.
Briefly, 10 x 106 cells were plated in 6 well plates overnight and were subsequently
treated with vehicle or MnP for 1 hour. Samples were collected and nuclear extracts were
obtained according to the kit manual procedures. Extracts were then mixed with free
transcription factor probes in binding buffer at room temperature for 30 minutes.
Unbound probe was then removed by centrifugation through an isolation column
equilibrated with binding buffer. Bound probes were then eluted and denatured in DNA
free ddH2O at 98°C for 5 minutes. Eluted probe was then hybridized to the hybridization
plate overnight at 42°C. Plate wells were then blocked in blocking buffer at room
temperature for 5 minutes followed by incubation with the diluted HRP-conjugates and
incubated at room temperature for 45 minutes. Wells were then washed 3 times and
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substrate was added to each well followed by a 1 minute incubation. Luminescence was
then evaluated with a 1 second integration time.
Western Blotting
Western blots were prepared as follows. 3.0 x 105 cells were lysed in standard ice
cold RIPA buffer with protease and phosphatase inhibitors for 30 minutes on ice. Cellular
debris was removed by centrifugation at 10,000 rpm for 10 minutes. Equal amounts of
protein were then diluted with 2x Laemmli sample buffer (Bio-Rad Laboratories;
Hercules, CA) and boiled at 95°C for 5 minutes. Samples were then resolved in a 10%
SDS-PAGE gel at 160 V for 90 minutes. Proteins were transferred to a nitrocellulose
membrane at 100 V for 60 minutes. Membranes were blocked with 5% milk in TBST
(pH=7.4) for 60 minutes before the indicated primary antibodies were administered and
incubated for 16 hours, overnight at 4°C. Membranes were washed with TBST and
incubated with HRP-conjugated secondary antibodies for 60 minutes prior to detection
with ECL reagent (GE Healthcare; Pittsburgh, PA) on x-ray film (Denville Scientific;
Holliston, MA). Protein quantitation was determined using image J software (NIH;
Bethesda, MD) by band intensity normalization to β-actin controls (n=3).
DNA Binding Assay
Cells (100 x 106 ) were plated overnight in 25 cm dishes and were treated with
vehicle or MnP for 1 hour. Samples were collected and washed with PBS. Samples were
then resuspended in buffer A (60 mM KCl, 15 mM NaCl, 0.5 mM spermidine, 15 mM
HEPES, 0.05% NP-40, containing protease and phosphatase inhibitors and containing 0.3
M sucrose). Samples were then mechanically lysed with a Teflon pestle homogenizer and
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centrifuged for 10 minutes at 3,500 rpm, 4°C. Samples were then resuspended in buffer A
containing 0.3 M sucrose (0.2% NP-40); 10 mL of 0.9M sucrose was added and samples
were centrifuged for 10 minutes at 3,500 rpm, 4°C. Nuclear pellets were collected and
resuspended in DNA binding buffer (20 mM TrisHCl pH 7.4, 185 mM NaCl, 5%
glycerol, 0.1% Triton X-100, 0.1% NP-40, containing protease and phosphatase
inhibitors). Samples were then briefly sonicated and biotinylated double stranded oligo
nucleotide containing tandem repeats of the consensus AP-1 DNA binding motif (5’Biotin-TGAG/CTCA-3’) was added (5 μg) with 3000-fold molar excess of salmon sperm
DNA. Samples were then incubated on ice for 1 hour and were subsequently centrifuged
at 3,500 rpm for 10 minutes at 4°C. Nuclear extracts containing the protein DNA
complex were then incubated with 40 μL of streptavidin linked sepharose beads (50%
slurry) for overnight at 4°C. Beads were then pelleted by centrifugation at 14,000 rpm for
15 minutes at 4°C and were subsequently washed twice with DNA binding buffer to
remove non-specific protein binding. Beads were then removed and bound protein was
collected by heating to 95°C in 2x loading buffer followed by centrifugation at 14,000
rpm for 15 minutes at 4°C. JunB protein was then evaluated by western blotting as
previously described.
Immunoprecipitation
MDSL cells (10 x 106 ) were plated in a 6 well plate and incubated in complete
growth medium overnight. Samples were then treated with vehicle (ddH2O) or 20 μM
MnP for 1hr. Cells were collected and washed twice with PBS. Cells were lysed in ice
cold RIPA buffer and were subsequently incubated on ice for 30 min. Cellular debris was
then pelleted by centrifugation at 10,000 rpm for 10 min at 4°C. Lysates were collected
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and protein concentration was measured via BCA assay; 20 ug of primary antibody was
added to 500 ug of lysate and samples were then incubated with rotation at 4°C
overnight. Protein A/G conjugated agarose beads (20 μL, 50% slurry) was added and
samples were incubated with rotation at 4°C overnight. Beads were then pelleted by
centrifugation at 14,000 rpm for 15 minutes at 4°C. Samples were then washed with
RIPA buffer and beads were pelleted for a second wash. Loading buffer (40 μL of 2x)
was then added and samples were heated at 95°C for 5 minutes. Samples were then
collected by centrifugation and were subsequently analyzed by Western blotting.
Biotin-1,3-cyclopentadione (BP-1) pulldowns were accomplished by treating 10 x
106 cells with vehicle or MnP for 1hr, washing cells in 1 mL of PBS, and resuspending
cells in PBS containing 5 mM BP-1 for 15 minutes at room temperature. Excess BP-1
was then removed by centrifugation and washing twice with PBS. Pellets were then
incubated for 30 minutes at room temperature to allow for the chemical modification of
sulfenic acid with BP-1. After 30 minutes samples were lysed in PBS, that was
previously rendered free of oxygen via nitrogen gas infusion, and containing 1% Triton
X-100, 0.5% NP-40, 2 mM iodoacetamide, ˃200 Units of bovine catalase for 30 minutes
at room temperature in the dark. Lysates were collected and 10 μg of protein was
aliquoted for loading controls. Streptavidin linked sepharose beads (50 μL,50% slurry)
was added to each sample followed by incubation overnight at 4°C with rotation after
which time samples were collected and analyzed by Western blot as described above.
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Lentiviral Production and Transduction
Separate lentiviral plasmids containing shRNA’s directed towards JunB and Ref-1
were obtained from GeneCopeia (Rockville, MD) and lentiviral particles were produced
in 293Ta cells according to the manufactures protocol. Briefly, 1.3 x 106 293Ta cells
were plated in a 10 cm dish. 48 hours later the cells were transfected with the lentiviral
plasmid and a packaging plasmid mix complexed with a transfection reagent. Fresh
media was placed in the dish 14 hours after transfection. Lentivirus was harvested 48
hours after transfection. Lentivirus was then purified by ultra-centrifugation at 25,000
rpm for 90 minutes. Supernatants were discarded into 20% bleach solutions and lentiviral
particles were resuspended in fresh IMDM media by aspiration (100x) followed by a 2
hour incubation period and another round of aspiration. Lentivirus was sterile filtered and
diluted in complete MDSL growth media. MDSL cells were then plated out in a 24 well
plate at 30,000 cells per well in 500 μL of lentiviral supernatant followed by a 48 hour
incubation period. Viral supernatants were then discarded to a 20% bleach solution and
cells were plated in fresh growth media for another 48 hours. Samples were collected and
sorted by flow cytometry based on protein tag expression. Sorted cells were then plated
in growth media containing 0.2 μg/mL puromycin for antibiotic selection and
establishment of stable knock down cell lines.
Statistics
Statistical analysis for immunoblotting comparing band intensity between
treatment and control groups for at least three replicate experiments was completed via ttest, significance is reported at p<0.05. Cell viability containing multiple drug
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concentrations of a single test group were completed by one-way ANOVA and those with
multiple test groups were completed by two-way ANOVA, with post hoc evaluation.
Transcriptional activity was completed with n=3 and error for fold change from vehicle
control is reported as standard deviation. Unless otherwise stated, all other error is
presented as the standard error of the mean derived from at least three experimental
replicates containing multiple measurements for each group.
Results
Our initial studies utilizing MnP have been accomplished in the WT C57BL6
background mouse model. This work has paved the way for a new understanding of how
redox stress levels differentially effect the hematopoietic stem cell and it’s environment
(256). Because we have found that MnP imparts a significant improvement to normal
HSC function, we have evaluated its potential as an anti-cancer agent. We first compare
MnP effects on malignant MDSL and normal mononuclear cells isolated from the bone
marrow of healthy individuals. We found a significant dose dependent increase in MnP
mediated cytotoxicity within the MDSL cell line (IC50= 31.3 μM, Figure 3.1A), with no
induced differentiation from the stem/progenitor (CD34+ CD38+) (Figure 3.1B). MnP
treatment of normal mononuclear blood cells (MNBC’s) results in improved overall
frequency of viable CD34+ cells with a highly significant increase in CD34+ CD38+ cells
(Figure 3.1 C-E). These results agree with our previous findings, which demonstrate MnP
mediated enrichment of hematopoietic function through the upregulation of antioxidant
capacity. This further supports the overall safety of MnP toxicity and founds future
efforts in characterization of MnP effect on whole niche dynamics. Furthermore, this
presents the possibility that MnP may differentially target intracellular redox states of cell
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populations that coexist, such as normal and malignant populations occupying the bone
marrow during malignant transformation and progression of disease.
To further investigate the effect of MnP on the intracellular malignant redox
environment, we evaluated the overall 2GSH/GSSG ratio via glutathione quantitation and
calculation of the half-cell reduction potential. Although there is some debate over the
relevance of GSH in some aspects of redox biology, HSC dependence on GSH/GSSG
metabolism is well documented. Because MnP is a redox active porphyrin that cycles the
complexed manganese through single electron transfer and the metabolism of 2GSH to
GSSG involves a two-electron process in which hydrogen ions are potentially liberated,
we not only have to accurately account for absolute analyte concentrations, but also for
any alterations to the intracellular pH after MnP treatment. Intracellular pH was measured
via BCECF fluorescence and was calculated using external standards equilibrated with
high potassium solutions via an antiporter at various pH values. We found that MnP
treatment does not significantly alter physiological intracellular pH (Table 3.1). We then
used the diameter of the cell measured by electrical impedance (Table 3.2) to calculate
the cellular volume, which was combined with dual analyte quantitation via LC-MS/MS
to calculate the intracellular molar concentrations of both reduced and oxidized
glutathione after MnP treatment (Table 3.3). MnP in fact does reduce cellular glutathione
levels, resulting in a decrease in the cellular reduction potential of approximately +10 mV
at both 4 and 16 hours of treatment (Figure 3.2). This indicates that MnP induces the
same mild ROS elevation in malignant cells, as it does in normal populations. Further
investigation of catalase inhibition revealed that MnP treatment causes an increase in
steady state hydrogen peroxide levels from 14 pM to approximately 20 pM. While no
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significant increase in catalase activity occurs, this fine alteration of the true intracellular
redox environment towards more oxidizing conditions is the key facet of MnP that allows
for differential targeting of malignant cells over their normal counter parts. Pretreatment
of the MDSL cells with PEG-catalase prior to MnP completely protects the MDLS cells
from MnP induced cytotoxicity (Figure 3.3). Thus, while this H2O2 production leads to
cellular protection and improved function in normal populations, the preclusion of
induced cytotoxicity by the pre-application of PEG-catalase demonstrates the opposite
and detrimental effect hydrogen peroxide has within the MDSL cell.
In order to determine which pathways may be regulated by MnP treatment within
the MDSL cell line, we performed an ELISA assay that contained binding motifs for
several redox sensitive transcription factors. We found that MnP treatment results in AP1 pathway activation (Figure 3.4A). These results were confirmed by the observation of
increased phosphorylation of several members of the MAP-kinase cascade, including Nterminal jun kinase (Figure 3.4B). This versatile group of transcription factors is
composed of Fos and Jun proteins that dimerize with various AP-1 partners, including
themselves, before DNA binding is activated (104, 187, 188). To elucidate which
member may be involved, we performed a series of immunoprecipitation experiments
across combinations of c-Jun, JunB, and JunD as no Fos proteins could be detected. From
these co-immunoprecipitations we determined the potential for JunB homodimerization
and subsequently confirmed the consistent activation of JunB after MnP treatment
(Figure 3.4C-D). Moreover, this activation was further confirmed by a DNA binding
assay utilizing a 5’-biotinylated oligonucleotide containing the AP-1 consensus DNA
binding sequence. Here, MnP treatment resulted in a greater pulldown of JunB in
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comparison to vehicle control confirming the MnP induced activation of JunB DNA
binding activity (Figure 3.4E).
The regulation and activation of the AP-1 transcription factors has been well
defined by JNK phosphorylation of c-jun; however, the lack of JNK docking sites and
alternative outcomes after phosphorylation with any other jun family members has led to
the identification of redox regulatory factors that interact with Jun proteins. Ref-1,
identified in the early 1990’s as a dual function protein, demonstrates strong redox
activity towards the AP-1 family proteins (238, 239, 242). Because of the alterations to
the intracellular redox environment introduced by MnP treatment, we investigated the
potential involvement of Ref-1 contributions to JunB activation. Upon treatment with
MnP we found that Ref-1 does co-immunoprecipitate with JunB in comparison to vehicle
control (Figure 3.5A-B). To confirm this interaction, we performed the reverse
immunoprecipitation and, in fact, JunB does co-precipitate with the Ref-1 pulldown
(Figure 3.5C-D). These robust and consistent results demonstrate targeted AP-1
activation differential to normal HSC counterparts.
The alteration of the MDSL cell redox environment, the production of
intracellular H2O2 and the subsequent interaction with Ref-1 strongly suggest that JunB
is subject to redox regulation via MnP treatment. The DNA binding region of Fos/Jun
proteins is highly conserved amongst family members. Within this motif, a single
cysteine reside resides adjacent to basic amino acids that make contact with the DNA
backbone upon transcriptional activation. There is some evidence that this residue retains
a diminished pka, potentially making it susceptible to oxidation via H2O2 produced by
MnP treatment. To investigate this, we utilized the chemical probe, biotin-1,395

cyclopentadione (BP-1), which specifically and faithfully reacts with sulfenic acid
cysteines that form via H2O2 oxidation (65, 168, 171). Treatment with MnP and
subsequent incubation with BP-1 allowed for the consistent pulldown of oxidized JunB
via streptavidin linked beads (Figure 3.6A-B). The clear involvement of both JunB and
Ref-1 in MnP induced cytotoxicity led us to confirm their implication through individual
knock downs within the MDSL cell line. However, the slow MDSL cell growth rate and
the inherent difficulty in transient transfection of suspension cells lead us to a lentiviral
based approach. We produced lentivirus containing shRNA directed toward JunB and
Ref-1 and transduced MDSL cell populations individually. Each knockdown cell type
was selected via FACS analysis using fluorescent tags and was then cultured in selection
media containing puromycin. This lead to the successful development of 100%
knockdown positive populations evidenced by the fluorescents tags demonstrated in
Figure 3.7 A & D (JunB KD-GFP; Fer-1 KD-mCherry). These populations display an
extremely efficient knockdown, as no detectible protein is found in comparison to equal
loading of the WT controls (Figure 3.7 B&E). Here, neither individual knockdowns
display any dose or time dependent cytotoxicity in response to MnP treatment compared
to the control MDSL parental cell line. These results clearly identify the activation and
involvement of JunB with Ref-1 in MnP mediated cytotoxicity within the MDSL cell line
and provide a potential druggable target for future development that is crucial to the
management of myeloid lineage populations within hematopoietic neoplasms.
Discussion
The myelodysplastic syndromes are a diverse set of myeloproliferative disorders
that have proven to be aggressive and difficult to treat. The MDS phenotype offers a
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window for the development of therapeutics that may demonstrate the advantage of
targeting molecular pathways prior to and during malignant transformation. The MDSL
cell line derived from a patient in the pre-leukemic stage of MDS demonstrates stem and
progenitor clonal characteristics through the expression of CD34, CD117, CD38, CD45
and CD33 (173, 174). These cells contain a variety of complex cytogenetic abnormalities
that contribute to the stem/progenitor dysplastic phenotype (130). Moreover, these cells
efficiently engraft into NSG and NSGS mice and demonstrate a latency period of
engraftment development (NSG, 55-56 days; NSGS, 20-28 days) within the bone marrow
and spleen before clonal expansion carrying to the peripheral blood, resulting in
peripheral blood cell suppression. These engraftments do respond to clinically relevant
dosing regimens of lenalidomide treatment at 25 mg/kg/day, M-F which has improved
erythropoiesis and T-cell activation in the face of pro-inflammatory cytokine suppression
(130, 173, 174). Limited access to primary patient samples makes this model an
important platform for the identification of molecular pathways and novel therapeutics
that focus on broad treatment of MDS expansion and restoration of normal
hematopoiesis, rather than individual targeted therapies.
We have recently identified the manganese porphyrin MnTnBuOE-2-PyP5+
(MnP) as a redox active compound that poses no toxicity to normal hematopoietic tissues,
but, in fact, aids normal hematopoietic function. MnP induced production of hydrogen
peroxide via metabolism of cellular superoxide results in Nrf2 activation and the
upregulation of antioxidant defense enzymes that include manganese superoxide
dismutase, catalase, and glutathione synthesis enzymes. MnP treatment in vitro and in
vivo results in improved CFC (colony forming cell assay) and CAFC (cobblestone area97

forming assay) performance, increased LSK frequency, and improved engraftment
demonstrated by serial bone marrow transplants through tertiary recipients (256). These
results led us to evaluate MnP effects in the MDSL cell line and resulted in the
identification of a molecular target within the AP-1 signaling pathway, JunB.
Treatment of the MDSL cell line with MnP results in a dose dependent increase in
cyto-toxicity through alteration of the intracellular redox state, demonstrated by a
decrease in the glutathione based cellular reduction potential and the increase in steady
state intracellular hydrogen peroxide concentrations. This alteration of the MDSL cellular
redox state, while somewhat mild, is significant because it ultimately results in AP-1
transcriptional activation through JunB oxidation and interaction with Ref-1. First
identified by Xanthoudakis and Curran (238-241), Ref-1 (APE-1) is an endonuclease
involved in various DNA repair pathways; however, Ref-1 has a dual function that
involves strong redox regulation of AP-1 family proteins. This function is sufficient to
result in AP-1 transcriptional activation and has a stronger effect than that of DTT in the
reduction of oxidized AP-1 proteins (239, 242).
The immunoprecipitation of JunB after MnP treatment demonstrates in an
increase in MnP mediated JunB-JunB dimer formation as well as an increase in JunBRef-1 interaction. The AP-1 family proteins belong to a family of basic leucine zipper
transcription factors composed of Fos-Jun family members. To date several elegant
crystal structure studies have characterized the DNA complex formation and the redox
regulation of Fos-Jun activity (70, 84, 249). These transcription factors contain a highly
conserved DNA binding region that contains an essential cysteine residue (Cys 285; bZIP
cysteine) surrounded by the basic amino acids responsible for contacting the DNA
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backbone upon transcriptional activation. These residues have the potential to withdraw
electron density from the bZIP cysteine, in effect lowering the cysteinyl pKa. This allows
for the formation of the thiolate anion cysteine, which can not only repel the DNA
backbone preventing transcriptional activation, but also makes this residue susceptible to
oxidation. Interestingly, in all of these studies, the authors note that cys 285 must be
mutated to serine in order to first, prevent protein oxidation, and second, to allow proteinDNA complex formation (70, 84, 249). While the most well characterized dimer of the
AP-1 family c-Jun-c-Jun in known to be regulated by the activity of N-terminal Jun
Kinase (JNK), c-Jun as well as other members of the AP-1 family are subject to redox
regulation (239, 240). In MDSL cells we have found that MnP treatment results in redox
regulated JunB activation, evidenced by MnP mediated JunB-DNA complex formation
and the MnP mediated formation of sulfenic acid cysteine within JunB via oxidation by
hydrogen peroxide, as demonstrated by JunB reaction with BP-1. We believe that MnP
mediated oxidation of JunB then recruits and requires Ref-1 mediated reduction of the
JunB cysteine residue. Individual lentiviral mediated knock down of both JunB and Ref-1
resulted in the protection of MDSL cells from MnP-induced cytotoxicity, further
confirming the importance of these mechanistic targets for MnP treatment of MDSL
cells.
The finding that MnP can induce JunB activation via redox control is potentially
very significant for the advancement of MDS therapy, as JunB has previously been
identified as a major contributor to the control of myeloid lineage cellular compartments.
Not only does JunB control the expansion of granulocyte-macrophage populations
through upregulation of p16INK4a, p18, and p57 JunB deficient mice develop significant
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myeloproliferative disorders that closely resemble myelodysplastic syndromes (99, 156159, 177). Wherein, loss of JunB expression leads to the loss of cell cycle control and
increases the proliferative capacity of LT-HSC without affecting their self-renewal
capacity. Thus, JunB inactivation may lead to clonal expansion without resulting in
complete bone marrow failure much like the transformation of a myeloproliferative
disorder to a malignant leukemia. Notably, MnP has demonstrated the ability to regulate
p16, which is an important cell cycle regulator controlling myeloid expansion and key
targets of JunB transcription (185, 231). MnP versatility as a therapeutic is further
supported by the recent discovery that the AP-1 transcription factors preferentially bind
to hemimethylated consensus DNA sequences (84). Taken together, these facets of MnP
activity and AP-1 function provide potentially safe therapies for individuals who are
refractory to first line treatments of hypomethylating agents as well as those who may not
tolerate aggressive AML therapies or allogenic bone marrow transplants.
Future efforts should be directed at further characterization of MnP control over AP-1
activation. The stable JunB and Ref-1 cell lines described here may be used to identify
MnP transcriptional regulation as well as key JunB targets. These cell lines also present
the opportunity to further quantify MnP mediated JunB oxidation. Although several
studies speculate a decreased cysteinyl pKa within the Jun DNA binding region, a pH
dependent DNA binding approach may narrow in on the exact nature of Jun redox
sensitivity.
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Figure 3.1 MnP toxicity in normal and malignant cells
A) MDSL dose-response curve was generated within a 95% confidence interval by treating
MDSL cells at various MnP concentrations for 48 hours and cytotoxicity evaluated by MTT
assay. B) MDSL cells were treated with MnP for 24 hours and potential differentiation was
observed by flow cytometry. C-E) Normal human bone marrow cells were treated with MnP for
24 hours and were subsequently evaluated for viability by PI staining and stem marker evaluation
by flowcytometry. Statistical analysis represents n=3 by one-way ANOVA with Tukey’s post hoc
analysis, error presented as SEM. * p<0.05, ** p<0.001, *** p<0.0001, **** p<0.00001
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Table 3.1 MnP Effect on Intracellular pH

Table 3.2 MnP Effect on Cellular Volume
Volume

Table 3.3 MnP Effect on Intracellular Glutathione Concentrations

Tables 3.1-3. 3) 3.1) Indicates the intracellular pH levels after MnP treatment in MDSL cells
measured by BCECF fluorescence. 3.2) shows average MDSL cellular diameter after MnP
treatment. 3.3) Intracellular molar concentrations calculated using quantitative LC-MS/MS
results and cell volume calculated from measured diameters, after MnP treatment.
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Figure 3.2 MnP effect on MDSL cellular reduction potential
Glutathione half-cell reduction potentials in vehicle and MnP
treated (20 μM) cells. Error is presented as SEM, n=3.
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Figure 3.3 MnP effect on intracellular H2O2
A) Intracellular steady state levels of hydrogen peroxide after 20 μM MnP treatment for 1
hour measured by catalase inhibition. B) Catalase activity in MDSL cells after MnP treatment
at time zero (no catalase inhibition). C) MTT assay for MDSL cells treated with MnP and/or
PEG-CAT. N=3, error presented as SEM, statistical analysis done by two-way ANOVA with
Tukey’s post hoc testing, or t-test where appropriate. * p<0.05.

104

Figure 3.4 MnP effect on transcriptional activation
A) Transcriptional ELISA array analysis of nuclear extracts from vehicle and MnP treated
MDSL cells (data shown as fold change from vehicle control, n=3). B) Western blot
analysis of MAPK pathway activation by detection with phosphor-antibodies after MnP
treatment. C) Immunoprecipitation followed by immunoblot analysis for activation of AP1 family transcription factors. D) Quantitation of JunB immunoprecipitation after vehicle
or MnP treatment in MDSL cells. E) Biotin-streptavidin DNA pulldown assay of nuclear
extract from MDSL cells treated with either vehicle or MnP for 1 hour. Statistical analysis
completed by two-way ANOVA and Tukey’s post hoc test or t-test where appropriate;
*p<0.05.
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Figure 3.5 MnP induces JunB interaction with Ref-1
A-D) Forward and reverse co-immunoprecipitation of JunB and Ref-1 in MDSL cells after
vehicle or MnP treatment for one hour. Quantitation n=3, statistical analysis done by t-test;
*p<0.05, **p<0.001.
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Figure 3.6 MnP induces oxidation of JunB
A-B) Biotin-streptavidin pull down of JunB with BP-1 reacted with JunB sulfenic acid
form cysteine after vehicle or MnP treatment. Quantitation n=3, error presented as standard
deviation, statistical analysis completed by t-test; *p<0.05.
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Figure 3.7 JunB and Ref-1 mediate MnP induced MDSL cell cytotoxicity
A&D) Flow cytometry analysis of WT and JunB (top) or Ref-1 (bottom) knockdown
populations for reporter tag. B&E) Western blot analysis for JunB (top) and Ref-1
(bottom) protein concentrations in WT control vs knockdown MDSL cells. C&F) MTT
assay after MnP treatment for JunB (top) and Ref-1 knockdown cells compared to WT
controls. Statistical analysis completed by two-way ANOVA and Tukey’s post hoc test,
n=3 error presented as SEM **p<0.001.
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Chapter Four: Targeting the Chemo-resistant Malignant Phenotype Through
Manipulation of the Intracellular Redox Environment
Introduction
Cancer treatments which exploit variations between normal and malignant redox
states are gaining validation through pre-clinical models as well as clinical trials. These
therapies include the use of pharmacological doses of ascorbate alone and in concert with
ionizing radiation, the application of polyphenyls, and the use of manganese porphyrins
(93, 126, 181, 210). Commandeering heightened cancer cell metabolism to produce
intracellular hydrogen peroxide concentrations detrimental to cancer cell survival are at
the heart of these therapeutic strategies. For example, in a pre-clinical glioblastoma
model, ascorbate treatment produces hydrogen peroxide that results in the disruption of
iron-sulfur metabolism leading to an increase in labile iron pools causing oxidative
damage at several cellular levels. Natural compounds such as β-phenylethyl
isothiocyanate (PEITC) have been effective in the treatment of Gleevec resistant CML
models that express the Bcr-Abl fusion protein. These studies are centered on the ROS
induced oxidative degradation of Bcr-Abl resulting from the generation of hydrogen
peroxide (253). Several manganese porphyrin compounds have recently demonstrated
cytotoxicity within different cancer models, including inflammatory breast cancer as well
as lymphoma models (15, 93, 210, 211). Reduction of metabolic superoxide to hydrogen
peroxide is the critical step in Mn-porphyrin based therapeutic approaches, one that can
be enhanced through co-treatment with ascorbate.
The current state of redox based therapeutic strategies relies heavily on malignant
cell sensitivity to peroxide generators. However, the very alterations that expose
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malignant cell types to redox based therapeutics may also provide ingrained defense
mechanisms that confer chemo-resistance to promising therapies that not only kill cancer
cells but protect off target normal tissues. The continued development and success of
redox therapy requires the consideration of approaches that circumvent developed or
innate chemo-resistant phenotypes. To date, potential therapies that demonstrate a robust
capacity to generate hydrogen peroxide predominantly describe alteration of the
malignant cell redox state through the depletion of cellular glutathione pools. While most
cell types harbor GSH concentrations in the 1-10 mM range, the extensive study of GSH
has revealed its clear importance to normal cellular function and redox maintenance. As
the dominating reducing species within the cell, researchers have found the relationship
of the GSH-GSSG redox couple with Gibb’s free energy, expressed through the Nernst
equation, as a useful tool for the examination of the cellular redox state (178). Beautifully
characterized by Schafer and Buettner (178), we can define various physiological
parameters along with the absolute concentration of the oxidized (GSSG) and reduced
(GSH) species to quantitate outcome responses to qualitative manipulations and cellular
states.
The cysteinyl pKa of GSH (~8.9) makes it is an average reducing agent alone, yet
we have previously thought that the high intracellular concentration of GSH could
compensate, making it a reducing mop that can neutralize oxidative threats that befall the
cellular milieu. We now know that high GSH concentrations also maintain the function of
glutathione metabolizing enzymes, such as glutathione S-transferases and glutaredoxins
that detoxify xenobiotics and reversibly modify protein thiols, as well as the glutathione
peroxidases that efficiently remove hydrogen peroxide (48). While considering only the
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“buffer” capacity of GSH is not enough to accurately describe the complex glutathione
system, pairing the quantitation of the GSH-GSSG half-cell reduction potential with
various enzyme kinetic data may help our incomplete understanding of how the
glutathione redox pair is utilized to manage the cellular redox state.
Glutathione’s diverse importance and versatility make the redox couple a prime
target for the development of both therapeutic strategies as well as chemo-resistant
phenotypes. It is no surprise then, that some cancers may utilize high intracellular
concentrations of GSH to demonstrate chemo-resistance against peroxide generating
therapies, as elevated GSH within malignant populations is a well-established
phenomenon. However, simply targeting overall cellular glutathione concentrations is an
undesirable approach, for not only have cancer cells shown the ability to survive with low
GSH concentrations, the level of depletion required for a desired effect delivers too many
negative off-target outcomes. However, we may find ways to manipulate glutathione
metabolism and utilization for therapeutic benefit. Because the ability to replenish GSH
after oxidative metabolism is so important to the function of glutathione utilization,
glutathione reductase activity is a key determinant for the maintenance of the GSH-GSSG
ratio.
GR is an oxido-reductase that completes two half reactions utilizing two NADPH
molecules for sequential reduction of an FAD domain which transfers electrons to active
site cysteines that complete the reduction of two molecules of glutathione disulfide. GR is
highly expressed in a wide variety of tissues and cancers, particularly in those pertaining
to the hemopoietic compartment. Thus, while targeting glutathione synthesis directly may
be too toxic to normal tissues, efficient inhibition of GR can potentially be utilized not
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only to enhance redox based therapies, but overcome chemo-resistant phenotypes in
which glutathione metabolism is employed to protect the malignant cell from excess
peroxide generation.
We have recently found that the Mn-porphyrin MnTnBuOE mediated production
of hydrogen peroxide poses no toxicity to normal tissues but actually enhances normal
stem cell function through the up-regulation of Nrf2 activity and increase in stem cell
antioxidant capacity. Conversely, others have reported its efficacy as an anti-cancer
agent, we have tested this compound’s cytotoxicity across several malignant models
derived from the hematopoietic compartment. Evaluation of several factors that
contribute to the management of the cellular redox state, in fact, reveal glutathione
reductase activity and the ability to perpetually reduce oxidized glutathione as a mediator
of chemo-resistance to MnTnBuOE treatment. Herein we investigate the principal of
targeting the cellular redox state as a means of circumventing chemoresistance to redox
active compounds.
Materials and Methods
Cell culture and treatments
K562 cells were cultured in IMDM media (ATCC; Manassas, VA) containing 1%
penicillin/streptomycin (Life Technologies; Grand Island, NY) and 10% FBS (GE
Healthcare; Pittsburgh, PA). HL-60 and MDSL cell lines were cultured in IMDM media
containing 1x penicillin/streptomycin and 20% FBS. MDSL cell culture media was
supplemented with 15 ng/mL human IL-3 (Peprotech; Rocky Hill, NJ). All cultures were
kept in a humid environment at 37° C supplemented with 5% CO2. Where indicated cells
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were treated with 50 μM buthionine-sulfoximine (BSO) (Sigma Aldrich; St. Louis, MO)
for 12-16 hours overnight. Glutathione reductase inhibition was achieved via 12-16 hours
overnight treatment with 7 μM carmustine (Enzo Life Sciences; Farmingdale, NY). MnP
was synthesized and characterized by Dr. Ines Batinic-Haberle and her colleagues at
Duke University School of Medicine; Durham, NC. Where indicated, MnP treatment was
combined with BSO and carmustine after overnight pre-treatments at indicated
concentrations. MnP treatment alone was accomplished by supplementing culture
medium with drug at indicated concentrations and durations. Where indicated cells were
treated with PEG-Catalase (Sigma Aldrich, St. Louis, MO) at a concentration of
approximately 80 Units/cell for 12-16 hours overnight.
Cell viability
Cell viability was determined by two different assays. First viability was
determined using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide) assay. Cells were plated at a density of 100,000-200,000 cells/mL and were
incubated with indicated drug treatments for 48 hours. At the time of analysis, samples
were collected and transferred to 5 mL round bottom polystyrene tubes (Corning;
Harrodsburg, KY), pelleted via centrifugation at 1300 rpm for 5 minutes and
subsequently washed twice with sterile PBS. Samples were then resuspened in DMEM
media containing no phenol-red supplemented with 0.5 mg/mL MTT reagent. Cells were
re-plated in a 96 well plate at 30,000 cells/well and incubated at 37° C (5% CO2) for 3.5
hours. Cells were then lysed with 1:1 (v/v) DMSO and isopropanol, then incubated for 25
minutes in the dark. Absorbance was then measured at 560 and 690 nm. Additionally,
cell viability was determined by flow cytometry. The number of cells within a viable gate
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separated from fragmented cellular debris was set in a dot-plot by the determination of
forward scatter vs side scatter. The number of cells in this gate divided by the total
number of events measured was taken as the percent of viable cells.
Glutathione quantitation and calculation of half-cell reduction potential
We have previously summarized the development, validation, and implementation
of simultaneous GSH and GSSG quantitation via LC-MS/MS. Briefly, treated samples
and controls were transferred, at 30,000 cells per sample, to 5 mL round bottom
polystyrene centrifuge tubes and were subsequently pelleted at 1300 rpm for 5 minutes.
Supernatants were vacuum aspirated and cells were subsequently lysed in an ice cold 2%
TCA solution containing 1 mM EDTA, vortexed for 30 seconds and incubated on ice for
15 min. Samples were then vortexed a second time and were further incubated on ice for
15 minutes. Cellular debris was then pelleted at 4,000 x g for 10 minutes and sample pH
was adjusted to 2.0 prior to LC-MS/MS analysis. Samples concentrations were calculated
based on external standard curve analysis with the linear form 𝑦 = 𝑚𝑥 + 𝑏. Sample
concentrations in ng/mL were converted to moles of analyte using the molar mass for
glutathione and glutathione disulfide. This conversion was then used to calculate the
molar analyte concentrations per cell after cellular volume determination.
Cellular diameter was determined via the Coulter principal and electrical
impedance. This was accomplished with a Scepter cell counter (Millipore Sigma;
Burlington, MA). Samples were collected, washed twice with PBS and analyzed with a
40 μm sensor. Average cellular diameters were then used in the equation for the volume
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of sphere, 𝑉 = 3 𝜋𝑟 3 , to calculate cellular volume. This value was used to divide analyte
concentrations (moles) resulting in cellular molar analyte concentrations.
Molar concentrations were then used to calculate the glutathione-based half-cell
reduction potential at 25°C, pH 7.0 as summarized by Schaffer and Buettner (178).

𝐸ℎ𝑐 = −240 − (

59.1
2

[𝐺𝑆𝐻]2

) log ( [𝐺𝑆𝑆𝐺] )

Western blotting
Western blots were prepared as follows. 3.0 x 105 cells were lysed in standard ice
cold RIPA buffer with protease and phosphatase inhibitors for 30 minutes on ice. Cellular
debris was removed by centrifugation at 10,000 rpm for 10 minutes. Equal amounts of
protein were then diluted with 2x Laemmli sample buffer (Bio-Rad Laboratories;
Hercules, CA) and boiled at 95°C for 5 minutes. Samples were then resolved in a 10%
SDS-PAGE gel at 160 V for 90 minutes. Proteins were transferred to a nitrocellulose
membrane at 100 V for 60 minutes. Membranes were blocked with 5% milk in TBST
(pH=7.4) for 60 minutes before the indicated primary antibodies were administered and
incubated for 16 hours, overnight at 4°C. Membranes were washed with TBST and
incubated with HRP-conjugated secondary antibodies for 60 minutes prior to detection
with ECL reagent (GE Healthcare; Pittsburgh, PA) on x-ray film (Denville Scientific;
Holliston, MA). Protein quantitation was determined using image J software (NIH;
Bethesda, MD) by band intensity normalization to β-actin controls (n=3).
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Enzyme activity determination
Glutathione reductase activity was measured with the OxiSelect kit from Cell
Biolabs. This assay utilizes consumption of NADPH in the presence of excess
glutathione disulfide to induce the interaction of reduced glutathione with a chromogen,
producing a colorimetric response that absorbs at 405 nm. Enzyme activity was measured
according to Cell Biolabs protocol. Treated samples and controls were collected and
washed twice with PBS before lysis in 1X assay buffer via 3 rounds of sonication in an
ice-cold water bath at 3 minutes per round with 30 second breaks between rounds for
vortex mixing. Samples were then combined with NADPH and chromogen assay
reagents in a 96 well plate. Glutathione disulfide was then added immediately prior to
analysis by kinetic measurement of absorbance at 405 nm at 1 minute intervals for 10
minutes. A standard curve with known concentrations of glutathione reductase enzyme
was evaluated simultaneous to the unknown samples. Background samples with no
glutathione disulfide present were subtracted from standards and samples. The average of
(n=3) slope was determined and used to calculate unknown glutathione reductase activity
in relation to the standard curve.
Total glutathione peroxidase activity was determined by a reaction coupled with
glutathione reductase and the consumption of NADPH evaluated by a decrease in
absorbance at 340 nm. This assay was accomplished with the Glutathione Peroxidase
assay kit obtained from Cayman Chemical; Ann Arbor, MI. The GPx assay was carried
out according to Cayman Chemical protocol. Samples and Controls were lysed in sample
buffer (50 mM Tris-HCl, pH 7.6, 5 mM EDTA, 1 mg/mL BSA) by sonication in an ice
cold water bath for 3 rounds of 3 minutes per round with 30 second breaks for vortex
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mixing. Samples were combined with a co-substrate mixture and assay buffer (50 mM
Tris-HCl, pH 7.6, 5 mM EDTA) and Cumene Hydroperoxide was added immediately
prior to measuring absorbance at 340 nm at 1 minute intervals for 10 minutes. A nonenzymatic background well was used to account for background absorbance loss and a
positive control well containing bovine erythrocyte GPx was used to confirm assay
activity. Two points of the absorbance curve were used to determine activity.
𝛥𝐴

/𝑚𝑖𝑛

0.19 𝑚𝐿

340
𝐺𝑃𝑥 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = (0.00373
) ∗ (0.02 𝑚𝐿)
𝜇𝑀−1

Measurement of catalase activity has been previously described (227). Briefly,
samples and controls were plated in 6 well plates, treated with 20 mM 3-aminotriazol
(Sigma Aldrich; St. Louis, MO) and subsequently harvested at 0, 5, 15, 30, 45, and 60
minutes. Cells were washed and subsequently lysed in in 250 uL of 50 mM phosphate
buffer pH 7.0 via sonication; 500 uL of 30 mM H2O2 in phosphate buffer was added to
1.0 mL of sample and the loss of absorbance at 240 nm was observed at 15 second
intervals for 2 minutes. The 0 time point was used to determine the first order rate
constant for catalase via the loss of H2O2.
ROS determination
General cellular ROS and the presence of H2O2 were determined via mean
fluorescence of H2DCFDA (Invitrogen; Waltham, MA). Pre-treatment of samples with
carmustine or PEG-Catalase was completed as indicated. Samples were then collected in
5 mL polystyrene round bottom tubes and were washed twice with PBS pH 7.4. Samples
were then resuspended in a 20 μg/mL solution of H2DCFDA or carboxy-DCFDA in
PBS, pH 7.4 and incubated in the dark at 37°C for 30 minutes. H2DCFDA and carboxy117

DCFDA solutions were then removed and samples were washed twice with PBS and
resuspended in complete culture medium without phenol red, containing either vehicle
control or 30 μM MnP. Samples were then incubated for 3 hours in the dark at 37°C, 5%
CO2. Media containing drug was then removed and samples were washed twice with
PBS prior to analysis by flow cytometery. Fluorescence was measured on a LSR II (BD
Biosciences; Franklin Lakes, NJ) with ex 488 nm, em 525 nm.
siRNA transfection
Transient knock down of glutathione reductase was achieved via siRNA
transfection. For each transfection, 0.75 μg of control or GR siRNA was diluted in 100
μL of transfection medium. Separately, 6 μL of transfection reagent was diluted in 100
μL of transfection medium. Media containing duplex siRNA was then slowly added to
the transfection reagent diluent dropwise. This solution was gently mixed and incubated
at room temperature for 30 minutes. The transfection complex was then diluted to 1 mL
and was subsequently used to gently suspend 5.0 x 105 cells which were then aspirated
into a single well of a 6 well plate. Transfections were then incubated for 8 hours at 37°C,
5% CO2 after which 1.0 mL of 2x complete growth medium was added to the
transfections prior to incubation for an additional 24 hours. Cells were then cultured
normally for 48 hours at which time they were evaluated for glutathione reductase
expression via western blot or used for experimental purposes.
Statistics
Statistical analysis for immunoblotting comparing band intensity between
treatment and control groups for at least three replicate experiments was completed via t118

test, significance is reported at p<0.05. Cell viability containing multiple drug
concentrations of a single test group were completed by one-way ANOVA and those with
multiple test groups were completed by two-way ANOVA, with post hoc evaluation.
Enzyme activity for multiple groups was evaluated by one-way ANOVA with post hoc
evaluation. Analyte and viability measurements for multiple drug treatment populations
were evaluated by two-way ANOVA with post hoc testing. siRNA transfections were
evaluated in comparison to control siRNA, n=3. All measurements for analytes, ROS,
and viability were completed in triplicate for each group. Unless otherwise stated, all
other error is presented as the standard error of the mean (SEM) derived from at least
three experimental replicates containing multiple measurements for each group.
Results
We set out to examine factors within the K562 redox environment in comparison to
others that may influence this treatment resistance. Since there is no single element of the cellular
redox environment that is an agreed upon marker for total redox status, we evaluated several
factors that are crucial to the management of oxidative stress. Simple analysis of enzyme
expression provided immediate clear targets that may be inducing chemo-resistance to H2O2
generated by MnP treatment. By comparison, the K562 cell line expresses high protein levels of
MnSOD, glutathione synthesis enzymes GCLG and GCLM, as well as high levels of glutathione
reductase (GR). Conversly the K562 cells demonstrate very low protein expression levels of
catalase and glutathione peroxidase-1, the front line enzymes utilized to metabolize hydrogen
peroxide (Figure 4.1A-F). This indicates that the resistant cell line utilizes another mechanism to
cope with H2O2 produced by high levels of MnSOD from metabolic superoxide.
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Because several isoforms of antioxidant enzymes exist and expression levels do not
always dictate catalytic efficiency, we went on to evaluate enzyme activity as well as the half-cell
reduction potentials for glutathione to gain further insight into the onset of the resistant
phenotype. We found that, indeed, the K562 cells demonstrate lower catalase and very low
relative GPx activity levels (Figure 4.3A-B). However, they demonstrate very high levels of GR
activity as well as a highly reduced glutathione reduction potential in comparison to not only the
normal human bone marrow controls but to other malignant cell types (Figure 4.3A-D). This
indicates that constant glutathione synthesis, metabolism, and turnover by glutathione reductase
works in combination to maintain a highly reduced environment in the face of high metabolic
stress that accompanies the heightened K562 growth rate (18-24 hr).
It is possible that highly reduced glutathione pools impart resistance to MnP treatment.
With this in mind, we pretreated K562 cells with BSO for 12-16 hours at 0.05 mM to inhibit
glutathione synthesis. Indeed this induced a significant depletion of reduced intracellular
glutathione (approximately 90%) and diminished glutathione disulfide levels to undetecTable
levels (Figure 4.4A-B). Interestingly, this concentration had a negligible effect on K562 cell
viability alone; however, combination with MnP induced a significant dose dependent cytotoxic
response not previously observed (Figure 4.4C).
While BSO has been investigated in the past, the off-target damage to normal HSC
glutathione pools is potentially too great to consider, thus we looked to exploit an alternative
portion of the glutathione metabolism pathway. The elevated expression and activity levels of GR
indicate that its function may be important to sustain K562 proliferation. As such, we used a GR
inhibitor (carmustine) in combination with MnP to determine the effects on the cellular redox
environment and potential response to redox based therapy. Carmustine (GR-I) was titrated and
the highest non-toxic concentration (7 μM) was chosen for combination treatment with MnP (data
not shown). Initial studies demonstrate efficient inhibition of glutathione reductase (over 50%,
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Figure 4.5B) with a 12-16 hour overnight treatment. This results in a significant alteration of the
2GSH/GSSG ratio, which dictates the cellular reduction potential, through the accumulation of
oxidized glutathione and elevated reduced glutathione due to synthesis (Figure 4.5A, C-E).
Additionally, this combination treatment induced a significant amount of DCF fluorescence in
comparison to any treatment alone. This high fluorescence level was predominantly quenched
through the pre-treatment with PEG-catalase, indicating that the major oxidative species produced
by combination glutathione reductase inhibition and MnP is in fact hydrogen peroxide (Figure
4.6). In concert with this production of H2O2, we observed a significant decrease in K562 cell
viability, demonstrated by increased cell fragmentation and loss of viable scatter. Importantly,
this loss of viability was rescued by pre-treatment with PEG-catalase, demonstrating H2O2 as the
culprit of cytotoxicity (Figure 4.7A-B). This indicates that glutathione reductase is a potential
mediator of chemo-resistance to redox therapeutics and potentially to others as well.
To confirm GR’s essential role in this phenotype, we took advantage of the aggressive
K562 cell nature and were able to perform transient siRNA knockdown of GR (Figure 4.8A). Just
as we observed with the inhibition of GR function, knockdown of GR resulted in a significant
alteration to the 2GSH/GSSG ratio (Figure 4.8C-E) and allowed for significant MnP mediated
increase in DCF fluorescence that was, again, quenched by pre-treatment with exogenous catalase
(Figure 4.8F-G). Similarly, knockdown combined MnP treatment induced a significant loss of
viable scatter that was recovered through the addition of catalase (Figure 4.9A-B). These results
confirm the involvement and importance of GR in the potential development and propagation of
chemo-resistance, particularly to redox active compounds. Overcoming chemo-resistance to
alternative therapies has an important role for the successful development of new therapeutics and
the ability to target glutathione metabolism outside of glutathione synthesis will aid future drug
development and hopefully, successful treatment paradigms.
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Discussion
Redox based therapeutics such as pharmacological ascorbate offer alternative treatment
options for aggressive cancers in patients who develop resistance or do not initially respond to the
standard of care options (181, 182). These drugs have a promising future, particularly within the
field of hematopoietic cancers because they may differentially target the malignant redox
environment while protecting off target tissues. However, the attributes of the redox environment
that lend themselves to some treatments may also develop resistant mechanisms in the future.
Successful and continued therapeutic development requires that we address such issues. We have
tested the novel manganese porphyrin MnTnBuOE against three malignant models within the
myeloid lineage and found varying cytotoxic results. The AML and MDS model cell lines HL-60
and MDSL both respond to MnP treatment at increasing doses; however, we have found that the
Gleevec resistant CML blast model K562 cells does not respond to MnP at similar concentrations
(Figure 4.1).

Continued development of cancer therapeutics which target the malignant cell
redox state through the production of H2O2 is a promising avenue for novel treatments
that are both safe and effective. The success of these treatments depends on the
consideration of complex scenarios that include the development or existence of
phenotypes refractory to alteration of the intracellular redox milieu. This includes cancer
cell utilization of the abundant glutathione pool which participates in a complex and
necessary landscape of oxidoreductase modifications and reactions. Because the
maintenance of cellular glutathione at some level is vital to the survival and growth of
normal, off target tissues, targeting the glutathione system for therapeutic benefit has
been difficult. Although there is some recent evidence to suggest that targeting
glutathione synthesis in combination with chemotherapy may improve treatment
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outcomes in multiple myeloma models, the off-target effects of this combination may still
prove to be too harsh (203). For these reasons, we set out to determine the effects of the
MnSOD mimetic MnTnBuOE.
We have recently found that this compound alters the cellular redox state via
production of H2O2, yet this increases stem cell number and improves HSC function
through the upregulation of Nrf2 activation (256). This demonstrates the potential for the
safe chemotherapeutic intervention of malignant phenotypes. Discovering variable
cytotoxic sensitivity in several cancerous cell lines derived from the myeloid lineage, we
went on to further access the redox factors that influence sensitivity to this H2O2
generator. The presentation of chemo-resistance to MnTnBuOE in the K562 cell line
compared to MDSL and HL-60 cell lines led to the discovery that the K562 cells
demonstrate heightened antioxidant capacity in the form of elevated GSH levels and
elevated cellular reduction potential that results from heightened glutathione reductase
activity. While MnTnBuOE induced K562 cytotoxicity via BSO pre-treatment
demonstrates the importance of the glutathione system to the chemo-resistant phenotype,
the inhibition of glutathione reductase and the alteration of the cellular reduction potential
presents glutathione homeostasis as a potential target to circumvent this resistance. Both
the inhibition of GR activity and the knock down of GR protein expression results in the
production of H2O2 when paired with MnTnBuOE treatment, as evidenced by quenching
DCF fluorescence through the application of exogenous catalase. Importantly, rescue of
MnTnBuOE mediated H2O2 production via catalase also rescues K562 cell viability. This
indicates that targeting glutathione metabolism through glutathione reductase activity
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rather than glutathione synthesis or overall glutathione concentrations offers an
alternative approach to target redox mediated chemotherapeutic resistance.
Because a highly efficient ability to reduce oxidized glutathione is an essential
component of the resistance phenotype, while the “glutathione addiction” typically found
in various cancers may be present, inhibition of synthesis and drastic depletion of
glutathione pools is not required for induction of cancer cell cytotoxicity. This presents
potential alternative approaches for targeting the glutathione system that may increase the
safety and efficacy of chemotherapeutic treatment as well as bringing interesting
questions concerning manipulation of the cancer cell redox state. For example, within the
bone marrow compartment, the location and quiescence of the normal HSC offer
protection and defense against oxidative insult. This combination may also mean that
latent HSC’s may not require extremely high glutathione reductase activity to maintain
reduced glutathione pools as well as a reduced cellular redox state. By contrast, the
relative inhibition of GR in cancer cells may be much more detrimental to cell survival.
Our results indicate that this combined with the H2O2 generator MnTnBuOE may offer
effective treatment of resistant cancer phenotypes without significantly damaging offtarget tissues.
The finding that glutathione reductase activity may be targeted to predispose
chemo-resistant cancer cells to hydrogen peroxide production brings up several
interesting questions that may not only improve therapeutic approaches but may also help
clarify our incomplete understanding of glutathione utilization and function. For example,
the structure-activity relationship of the MnTnBuOE allows for its accumulation in
subcellular locations, particularly with-in the mitochondria (12, 13, 15). This is
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significant as the majority of metabolic superoxide is produced in mitochondria. Studies
in yeast have revealed that GR has been found in the cytosol and the mitochondrial
matrix but not in the mitochondrial inner membrane space (IMS). Both the mitochondrial
matrix and the IMS have very high 2GSH/GSSG ratios, yet while IMS glutathione can be
replenished from the cytosol, sources of GSH transport into the mitochondrial matrix are
less apparent (25). Although GSSG can be exported from the matrix to aid in reduction
potential maintenance, deletion of GR (Grl1) reveals that the IMS can recover normal
GSH levels after oxidative insult yet the glutathione reduction potential within the
mitochondrial matrix does not recover. This indicates that GR activity is essential to
maintain mitochondrial matrix reduction potential (25). Loss of this ability may then
hamper the activity of glutathione peroxidase, exposing mitochondria to H2O2 production
through superoxide metabolism. Future investigations should address mitochondrial H2O2
production via GR inhibition and manganese porphyrin treatment and whether or not this
signal is significant enough to induce cancer cell death.
Additionally, our results indicate that not only is the ability to reduce oxidized
glutathione important but that the actual 2GSH/GSSG redox potential may have some
effect on overall antioxidant capacity. Future experiments should examine how artificial
manipulation of the 2GSH/GSSG ratio affects various aspects of the cellular redox state
and its functional maintenance. Recently, the GSSG mimetic NOV-002, which is a
racemate of oxidized glutathione and cisplatin (1000:1), has been characterized. This
compound has demonstrated inhibition of cancer proliferation and survival (49).
Additionally, NOV-002 has combated cyclophosphamide induced HSPC suppression.
Within the HL-60 AML model, NOV-002 activates p38 MAPK and JNK, which are
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known regulators of HSPC proliferation; however, treatment did not inhibit HL-60 cell
proliferation (95, 213-215, 222). The cytoprotective effect of this GSSG mimetic may
offer promising therapeutic developments in the future. As we have shown that GR
inhibition leads to an accumulation of intracellular GSSG and departure of the
2GSH/GSSG ratio from the homeostatic “normal” potential within chemo-resistant
cancer cells, artificial manipulation of GSSG levels with pure oxidized glutathione may
predispose cancer cells to H2O2 toxicity via co-treatment with an H2O2 generator. The
effectiveness of this approach may depend on the basal glutathione reduction potential of
a given cancer phenotype. In this case, the cytoprotective effects of GSSG in normal
tissues would potentially improve this chemotherapeutic approach.
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Figure 4.1 MnP cytotoxicity in malignant cells
48 hour MTT assay for MnP induced cytotoxicity in three different malignant cell
lines K562, HL-60, and MDSL. Statistical analysis done by two-way ANOVA with
Tukey’s post hoc test, n=3, error presented as SEM; *p<0.05
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Figure 4.2 Antioxidant enzyme expression in malignant cells
A-F) Antioxidant enzyme expression in three different malignant cell lines.
Quantitation of n=3, error expressed as standard deviation, statistical test done by
one-way ANOVA with multiple comparison Tukey’s post hoc test; *p<0.05
**p<0.001 ***p<0.0001
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Figure 4.3 Antioxidant enzyme activity and intracellular glutathione reduction potentials
in malignant cells
A) Catalase activity in 3 malignant cell lines determined at time 0 of catalase inhibition. B)
Total glutathione peroxidase activity determined in 3 malignant cell lines. C) Glutathione
reductase activity in 3 malignant cell lines. D) Glutathione half-cell reduction potentials in 3
malignant cell lines and compared to normal human bone marrow, determined by LC-MS/MS
quantitation. Statistical analysis for n=3 determined by ANOVA test with unpaired parameters
with Tukey’s post hoc testing; error expressed as SEM, *p<0.05, **p<0.001.

129

Figure 4.4 Glutathione depletion in K562 cells
A) LC-MS/MS chromatogram of K562 cell lysate depicting quantitation and depletion of
reduced and oxidized glutathione after treatment with BSO. B) Graphical quantitation of
GSH after BSO treatment. C) 48 hour MTT assay for K562 cell cytotoxicity after
combination treatment BSO and MnP. Statistical analysis for n=3 done by two-way
ANOVA and multiple comparisons to controls with Tukey’s post hoc test or t-test where
appropriate Error reported as SEM; *p<0.05, **p<0.001.
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Figure 4.5 Glutathione reductase inhibition in K562 cells
A) LC-MS/MS chromatogram of K562 cell lysate depicting quantitation of reduced and
oxidized glutathione after treatment with glutathione reductase inhibitor. B) Graphical
quantitation of GR activity after inhibition. C-E) Changes in reduced and oxidized
glutathione concentrations leading to an alteration of the 2GSH/GSSG ratio after
glutathione reductase inhibition. Statistical analysis for n=3 done by t-test and Error
reported as SEM; *p<0.05, **p<0.001.
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Figure 4.6 GR inhibition allows for MnP induced production of H2O2
A-B) DCF fluorescence in K562 cells after treatment with GR-I, MnP, GRI+MnP+PEG-CAT, A-histogram representation of the geomean DCF fluorescence
and B-graphical representation. Statistical analysis done for n=3 with two-way
ANOVA and Tukey’s post hoc test, *p<0.05. **p<0.001.
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Figure 4.7 GR inhibition sensitizes K562 cells to MnP induced cytotoxicity
A) Graphical representation of K562 cell viability after combination treatments with GR-I,
MnP, and PEG-CAT. B) Representative scatter plots. Statistical analysis done for n=3 with
two-way ANOVA and Tukey’s post hoc test, *p<0.05. **p<0.001.
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Figure 4.8 GR knockdown alters K562 cellular redox state
A-B) Western blot and graphical quantitation of glutathione reductase knockdown in
K562 cells. C-D) Graphical representation of intracellular glutathione quantitation and
alteration of glutathione levels after GR knockdown leading to an alteration of the
2GSH/GSSG ratio. F-G) Histogram and graphical representation of geometric mean DCF
fluorescence in control and GR knockdown cells after treatment with MnP and PEGCAT. Statistical analysis done for n=3 with two-way ANOVA and with Tukey’s post hoc
test or t-test where appropriate, *p<0.05.
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Figure 4.9 GR knockdown sensitizes K562 cells to MnP induced cytotoxicity
A) Graphical representation of K562 cell viability after combination treatments with GR
knockdown, MnP, and PEG-CAT. B) Representative scatter plots. Statistical analysis done for
n=3 with two-way ANOVA and Tukey’s post hoc test, *p<0.05. **p<0.001.
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Conclusions
Throughout this work I have described the current state and directions of redox
therapies for hematopoietic diseases, the development and implementation of a novel
method validated for the analysis of the hematopoietic stem cell and leukemic stem cell
redox states, and the identification of therapeutic targets that may be utilized for the
treatment of aggressive neoplastic malignancies as well as the circumvention of chemoresistance to develop safer, more effective treatment plans. It is my hope and my intent to
expand this LC-MS/MS methodology to an ultra-high-pressure liquid chromatography
platform that will enable much greater sensitivity and allowance for analysis of LT-HSC
population as well as sub-cellular compartments such as nuclear and mitochondrial
fractions. This will further our understanding of glutathione’s role in the redox
environments. As much as we know, our full understanding into the underpinnings of
glutathione function is far from complete. For example, many cells can survive with low
glutathione levels, so does this leave GSH-GSSG to be a metabolic co-factor rather than
an essential reducing agent? Moreover, in the face of oxidative insult, is maintenance of
the GSH/GSSG reduction potential the most important facet for maintaining global redox
regulation and does a slight change in electromotive force alter downstream protein and
pathway function at low but significant levels?
The utilization of MnP and identification of molecular targets has of course raised
many questions in the face of my progress. The first of which is, where in the cell are
specific redox signals being generated? Transient H2O2 signals may travel through
various compartments, yet this seems unlikely due to the abundance and efficiency of
antioxidant enzymes. This gives rise to the potential for the discovery of novel signal
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mediators that carry out oxidative signaling over longer distances. More focus needs to be
spent on this aspect as location and strength of signal generation serve as important
indicators of successful therapeutic development as well as improving global treatments
that surpass untested “personalized” therapies.
The fact that JunB plays a crucial role in myeloid lineage development and
maturation makes it an attractive therapeutic target. I have found that MnTnBuOE can
generate H2O2 that results in the transient oxidation of JunB leading to its transcriptional
activation. While this oxidation and subsequent activation must occur in the nucleus, we
do not know exactly where the H2O2 signal is initially generated. We know that
MnTnBuOE is generally targeted to the mitochondria but given the substantial
antioxidant capacity of the mitochondria, it seems unlikely that H2O2 generated within
would ever reach the nucleus in high enough concentrations to generate JunB activation.
If this is the case, future drug design may focus on structure activity relationships that
target redox cycling therapeutics to the nucleus so that this type of signal may generated
more efficiently. This approach would aid an increase in drug safety profiles as well as
combat the potential of limited bioavailability to the bone marrow compartment.
The complex nature of the cellular redox milieu offers opportunity in exploitation
of small differences within basic biology inherent to disease and normal cell types. This
makes site directed and signal specific redox therapies a promising field for future drug
discovery.

137

List of Abbreviations:
ABCG2 = ATP Binding Cassette subfamily G member 2
ALL = Acute Lymphoblastic Leukemia
AML = Acute Myeloid Leukemia
ANT = Adenine Nucleotide Translocase
AP-1 = Activating Protein-1
Atm = Ataxia-telangiectsia mutated
ATP = Adenosine Tri-phosphate
ATRA = all-trans Retinoic Acid
BCL-2 = B Cell Lymphoma 2
BCR-Abl = Breakpoint Cluster Region-Abl Kinase fusion protein
BM = Bone Marrow
BSO = Buthionine Sulfoximine
CAT = Catalase
CD34 = Cluster of Differentiation Protein 34
CD38 = Cluster of Differentiation Protein 38
CD33 = Cluster of Differentiation Protein 33
CD90 = Cluster of Differentiation Protein 90
CD133 = Cluster of Differentiation Protein 133
CD123/IL-3R = Cluster of Differentiation Protein 123/Interleukin-3 Receptor
CD45RA (PTPRC) = Cluster of Differentiation Protein 45 isofrom A (Protein Tyrosine
Phosphatase, Receptor Type C isoform A
CD49f = Cluster of Differentiation Protein 49f (Integrin α6)
c-Kit/CD117 = Tyrosine Protein Kinase KIT/ Cluster of Differentiation Protein 117
CLP = Common Lymphoid Progenitor
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CML = Chronic Myelogenous Leukemia
CSC = Cancer Stem Cell
CXCR4 = Chemokine Receptor type 4
DCF-DA = 2’-7’-dichlorofluorescence diacetate
Del5q = Myelodysplastic 5q Deletion Syndrome
DOX/ADR = Doxorubicin/Adriamycin
DPI = Diphenylene Iodonium
DZNep = 3-Deazaneplanocin
ETP = Etoposide
ETS = E26 Transformation Specific
FLT3-ITD = FMS like Tyrosine Kinase 3-Internal Tandem Repeat
Foxo3a = Forkhead box O3a
GCL = γ-glutamylcysteine synthetase
GCLC = Glutatmate-cysteine ligase catalytic subunit
GCLM = Glutatmate-cysteine ligase regulatory subunit
G-CSF = Granulocyte-Colony Stimulating Factor
GMP = Granulocyte Macrophage Progenitor
GPx = Glutathione Peroxidase
GR = Glutathione Reductase
GSH = Reduced Glutathione
GSSG = Oxidized Glutathione
GST = Glutathione-S-Transferase
Gy = Gray
.
HO = Hydroxyl Radical
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H2O2 = Hydrogen Peroxide
HOXA9 = Homeobox A9 protein
HSC = Hematopoietic Stem Cell
HSPC = Hematopoietic Stem/Progenitor Cell
IDH1 = Isocitrate Dehydrogenase 1
IKK2 = IKB Kinase 2
JNK = Jun N-terminal Kinase
Ki-67 = MKI67 Antigen KI-67
LEN = Lenalidomide
Lin = Lineage
LMPP = Lymphoid Primed Multipotent Progenitor
LSC = Leukemic Stem Cell
LSD1 = Lysine Specific Histone Demethylase 1A
LSPC = Leukemic Stem/Progenitor Cell
LTC-IC = Long Term Culture-Initiating Cell
LSK = Lin-/ Sca-1+/c-Kit+
LT-HSC = Long-Term Hematopoietic Stem Cell
MDS = Myelodysplastic Syndrome
MEP = Megakaryocyte-Erythroid Progenitor
MLL/ENL = Mixed Lineage Leukemia/Eleven Nineteen Leukemia
MM = Multiple Myeloma
MnTE/MnTE-2-PyP5+ = Mn (III) meso-tetrakis (N-ethylpyridinium-2-yl) porphyrin
MnTnBuOE/MnTnBuOE-2-PyP5+ = Mn (III) meso-tetrakis(N-(nbutoxyethyl)pyridinium-2-yl) porphyrin
MnSODTgH = transgenic mice overexpressing MnSOD
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MPD = Myeloproliferative Disorder
MPP = Multipotent Progenitor Cell
MRP1/ABCC1 = Multidrug Resistant Protein 1/ATP Binding Cassette subfamily C
member 1
MTX = Methotrexate
NAC = N-acetyl-L-cysteine
NADPH = Nicotinamide Adenine Dinucleotide Phosphate
NF-kB = Nuclear factor-κB
NOX = NADPH Oxidase
Nq01 = NAD(P)H dehydrogenase quinone 1
Nrf2 = Nuclear factor (erythroid-derived 2)-like 2
NUP98 = Nuclear Pore Complex Protein 98
O2 = Molecular Oxygen
.
O2 - = Superoxide

ONOO- = Peroxynitrite
PETIC = β-phenylethyl isothiocyanate
PLM = Piperlongumine
PRC2 = polycomb-repressive complex-2
PTEN/PI3K/AKT = Phosphatidylinositol-4,5-bisphosphate 3-kinase/Protein Kinase B
PTL = Parthenolide
p38 MAPK = p38 Mitogen Activated Protein Kinase
p14ARF = p14 Alternate Reading Frame Tumor Suppressor
p15INK4B = Cyclin Dependent Kinase 4 Inhibitor B
p16INK4A = Cyclin Dependent Kinase Inhibitor 2A
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p18INK4C = Cyclin Dependent Kinase 4 Inhibitor C
p19ARF = Cyclin Dependent Kinase 4/6 Inhibitor
p21CIP = Cyclin Dependent Kinase Inhibitor 1
Rho = Rho GTPase
ROS = Reactive Oxygen Species
Sca-1 = Stem Cell Antigen 1
SOD1 = Copper-Zinc Superoxide Dismutase
SOD2 = Manganese Superoxide Dismutase
SOD3 = Copper-Zinc Extracellular Superoxide Dismutase
ST-HSC = Short-Term Hematopoietic Stem Cell
TBI = Total Body Irradiation
TCP = trans-2-phenylcyclopropylamine
TKI = Tyrosine Kinase Inhibitor
TNF = Tumor Necrosis Factor
TP53 = Tumor Protein 53
TRAIL = TNF-related Apoptosis Inducing Ligand
TXN = Thioredoxin
TXNIP = Thioredoxin Interacting Protein
TXNR = Thioredoxin Reductase
UPC1/3 = Uncoupling Protein 1/3
53BP1 = p53 Binding Protein
5FU = Fluorouracil
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